UA95244C2 - Соединения и способ модулирования активности киназ, и показания для их применения - Google Patents

Соединения и способ модулирования активности киназ, и показания для их применения

Info

Publication number: UA95244C2
Authority: UA; Ukraine
Prior art keywords: compounds; methods; kinase modulation; indications therefor; indications
Prior art date: 2005-06-22

Application number

UAA200800780A

Other languages

English (en)

Ukrainian (uk)

Inventor

Прахбха Н. Ибрахим

Дин Р. Артис

Раян Бремер

Шумее Мамо

Марика Неспи

Чао Жанг

Джяжонг Жанг

Йонг-Лианг Жу

Джеймс Цаи

Клаус-Петер Хирт

Гидеон Боллаг

Уэйн СПЕВАК

Ханна Чо

Семюэл Дж. Джилетт

Гуаксям Ву

Хонгяо Жу

Шенгхуа Ши

Original Assignee

Плексикон, Инк.

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2005-06-22

Filing date

2006-06-21

Publication date

2011-07-25

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37033831&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UA95244(C2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2006-06-21 Application filed by Плексикон, Инк. filed Critical Плексикон, Инк.

2011-07-25 Publication of UA95244C2 publication Critical patent/UA95244C2/ru

Links

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
- A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C37/00—Preparation of compounds having hydroxy or O-metal groups bound to a carbon atom of a six-membered aromatic ring
- C07C37/62—Preparation of compounds having hydroxy or O-metal groups bound to a carbon atom of a six-membered aromatic ring by introduction of halogen; by substitution of halogen atoms by other halogen atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C39/00—Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a six-membered aromatic ring
- C07C39/24—Halogenated derivatives
- C07C39/26—Halogenated derivatives monocyclic monohydroxylic containing halogen bound to ring carbon atoms
- C07C39/27—Halogenated derivatives monocyclic monohydroxylic containing halogen bound to ring carbon atoms all halogen atoms being bound to ring carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C45/00—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C45/00—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
- C07C45/61—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups
- C07C45/67—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton
- C07C45/673—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton by change of size of the carbon skeleton
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C45/00—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
- C07C45/61—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups
- C07C45/67—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton
- C07C45/68—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton by increase in the number of carbon atoms
- C07C45/70—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton by increase in the number of carbon atoms by reaction with functional groups containing oxygen only in singly bound form
- C07C45/71—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton by increase in the number of carbon atoms by reaction with functional groups containing oxygen only in singly bound form being hydroxy groups
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C47/00—Compounds having —CHO groups
- C07C47/52—Compounds having —CHO groups bound to carbon atoms of six—membered aromatic rings
- C07C47/56—Compounds having —CHO groups bound to carbon atoms of six—membered aromatic rings containing hydroxy groups
- C07C47/565—Compounds having —CHO groups bound to carbon atoms of six—membered aromatic rings containing hydroxy groups all hydroxy groups bound to the ring
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C47/00—Compounds having —CHO groups
- C07C47/52—Compounds having —CHO groups bound to carbon atoms of six—membered aromatic rings
- C07C47/575—Compounds having —CHO groups bound to carbon atoms of six—membered aromatic rings containing ether groups, groups, groups, or groups
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring

UAA200800780A 2005-06-22 2006-06-21 Соединения и способ модулирования активности киназ, и показания для их применения UA95244C2 (ru)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US69296005P	2005-06-22	2005-06-22
US73152805P	2005-10-28	2005-10-28

Publications (1)

Publication Number	Publication Date
UA95244C2 true UA95244C2 (ru)	2011-07-25

Family

ID=37033831

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
UAA200800780A UA95244C2 (ru)	2005-06-22	2006-06-21	Соединения и способ модулирования активности киназ, и показания для их применения

Country Status (35)

Country	Link
US (10)	US7863288B2 (ru)
EP (3)	EP3088400A1 (ru)
JP (1)	JP5007304B2 (ru)
KR (1)	KR101125919B1 (ru)
CN (3)	CN102603581B (ru)
AR (2)	AR054624A1 (ru)
AT (1)	ATE518860T1 (ru)
AU (1)	AU2006261993B2 (ru)
BR (1)	BRPI0611863B1 (ru)
CA (1)	CA2613015C (ru)
CR (2)	CR9677A (ru)
CY (2)	CY1111996T1 (ru)
DE (1)	DE122012000043I1 (ru)
DK (2)	DK2395004T3 (ru)
EC (1)	ECSP088121A (ru)
ES (2)	ES2565992T3 (ru)
HK (2)	HK1114610A1 (ru)
HU (2)	HUE027370T2 (ru)
IL (1)	IL188248A (ru)
LU (1)	LU92035I2 (ru)
MA (1)	MA29612B1 (ru)
MX (1)	MX2007016463A (ru)
MY (2)	MY153898A (ru)
NO (2)	NO333913B1 (ru)
NZ (1)	NZ565255A (ru)
PE (1)	PE20070100A1 (ru)
PL (2)	PL1893612T3 (ru)
PT (1)	PT1893612E (ru)
RS (1)	RS52010B (ru)
RU (3)	RU2418800C2 (ru)
SI (2)	SI1893612T1 (ru)
TW (3)	TWI522337B (ru)
UA (1)	UA95244C2 (ru)
WO (2)	WO2007002433A1 (ru)
ZA (4)	ZA200711152B (ru)

Families Citing this family (407)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP1696920B8 (en)	2003-12-19	2015-05-06	Plexxikon Inc.	Compounds and methods for development of ret modulators
PL2332940T3 (pl)	2004-03-30	2013-03-29	Vertex Pharma	Azaindole użyteczne jako inhibitory JAK i innych kinaz białkowych
US7498342B2 (en)	2004-06-17	2009-03-03	Plexxikon, Inc.	Compounds modulating c-kit activity
US8969379B2 (en)	2004-09-17	2015-03-03	Eisai R&D Management Co., Ltd.	Pharmaceutical compositions of 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7=methoxy-6-quinolinecarboxide
KR20080027775A (ko)	2005-05-17	2008-03-28	플렉시콘, 인코퍼레이티드	피롤(２,３-ｂ)피리딘 유도체 단백질 키나제 억제제
CN102603581B (zh)	2005-06-22	2015-06-24	普莱希科公司	作为蛋白质激酶抑制剂的吡咯并[2,3-b]吡啶衍生物
CN102127078A (zh)	2005-07-14	2011-07-20	安斯泰来制药株式会社	Janus激酶3的杂环类抑制剂
KR20080026654A (ko)	2005-07-14	2008-03-25	아스텔라스세이야쿠 가부시키가이샤	헤테로시클릭 야누스 키나제 3 억제제
WO2007015578A1 (ja)	2005-08-02	2007-02-08	Eisai R & D Management Co., Ltd.	血管新生阻害物質の効果を検定する方法
EP1938842A4 (en) *	2005-09-01	2013-01-09	Eisai R&D Man Co Ltd	METHOD FOR PRODUCING A PHARMACEUTICAL COMPOSITION COMPRISING IMPROVED CRASHING CHARACTERISTICS
MY162590A (en)	2005-12-13	2017-06-30	Incyte Holdings Corp	Heteroaryl substituted pyrrolo[2,3-b] pyridines and pyrrolo[2,3-b] pyrimidines as janus kinase inhibitors
BRPI0706537A2 (pt)	2006-01-17	2011-03-29	Vertex Pharma	azaindóis úteis como inibidores de janus cinases
EP1979353A2 (en) *	2006-01-19	2008-10-15	OSI Pharmaceuticals, Inc.	Fused heterobicyclic kinase inhibitors
WO2007116866A1 (ja)	2006-04-03	2007-10-18	Astellas Pharma Inc.	ヘテロ化合物
CA2652442C (en)	2006-05-18	2014-12-09	Eisai R & D Management Co., Ltd.	Antitumor agent for thyroid cancer
US20090306126A1 (en) *	2006-05-22	2009-12-10	Astrazeneca Ab	Indole Derivatives
WO2008003736A1 (en) *	2006-07-06	2008-01-10	Solvay Pharmaceuticals B.V.	Azaindole derivatives with a combination of partial nicotinic acetylcholine receptor agonism and dopamine reuptake inhibition
US7964728B2 (en)	2006-07-06	2011-06-21	Solvay Pharmaceuticals B.V.	Azaindole derivatives with a combination of partial nicotinic acetyl-choline receptor agonism and dopamine reuptake inhibition
GB0617161D0 (en) *	2006-08-31	2006-10-11	Vernalis R&D Ltd	Enzyme inhibitors
EP2081435B1 (en)	2006-09-22	2016-05-04	Pharmacyclics LLC	Inhibitors of bruton's tyrosine kinase
WO2008063888A2 (en) *	2006-11-22	2008-05-29	Plexxikon, Inc.	Compounds modulating c-fms and/or c-kit activity and uses therefor
WO2008079909A1 (en) *	2006-12-21	2008-07-03	Plexxikon, Inc.	Pyrrolo [2,3-b] pyridines as kinase modulators
PE20081581A1 (es) *	2006-12-21	2008-11-12	Plexxikon Inc	COMPUESTOS PIRROLO[2,3-b]PIRIDINAS COMO MODULADORES DE QUINASA
WO2008080001A2 (en) *	2006-12-21	2008-07-03	Plexxikon, Inc.	Compounds and methods for kinase modulation, and indications therefor
EP2815750A1 (en)	2006-12-21	2014-12-24	Vertex Pharmaceuticals Incorporated	5-cyano-4-(pyrrolo [2,3b] pyridine-3-yl)-pyrimidine derivatives useful as protein kinase inhibitors
EP2560007A1 (en) *	2007-03-28	2013-02-20	Pharmacyclics, Inc.	Identification of bruton's tyrosine kinase inhibitors
US20120101113A1 (en)	2007-03-28	2012-04-26	Pharmacyclics, Inc.	Inhibitors of bruton's tyrosine kinase
JP5926487B2 (ja)	2007-04-13	2016-05-25	デイナファーバーキャンサーインスティチュート，インコーポレイテッド	ＥｒｂＢ療法に耐性である癌を治療するための方法
GB0710528D0 (en) *	2007-06-01	2007-07-11	Glaxo Group Ltd	Novel compounds
EP3495369B1 (en)	2007-06-13	2021-10-27	Incyte Holdings Corporation	Use of salts of the janus kinase inhibitor (r)-3-(4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h- pyrazol-1-yl)-3- cyclopentylpropanenitrile
US20100190777A1 (en)	2007-07-17	2010-07-29	Plexxikon Inc.	Compounds and methods for kinase modulation, and indications therefor
MX2010001636A (es) *	2007-08-14	2010-03-15	Hoffmann La Roche	Derivados de pirazolo[3,4-d]-pirimidina como agentes antiproliferativos.
WO2009026239A1 (en) *	2007-08-17	2009-02-26	University Of Maryland, Baltimore	Small molecule inhibitors of lck sh2 domain binding
JP2009077712A (ja)	2007-09-11	2009-04-16	F Hoffmann La Roche Ag	Ｂ−Ｒａｆキナーゼ阻害剤に対する感受性についての診断試験
DE102007045956A1 (de)	2007-09-26	2009-04-09	Bayer Cropscience Ag	Wirkstoffkombination mit insektiziden und akariziden Eigenschaften
DE102007045919B4 (de)	2007-09-26	2018-07-05	Bayer Intellectual Property Gmbh	Wirkstoffkombinationen mit insektiziden und akariziden Eigenschaften
WO2009054941A1 (en)	2007-10-25	2009-04-30	Merck & Co., Inc.	Therapeutic compounds
US8426396B2 (en) *	2008-01-08	2013-04-23	Shriners Hospitals For Children	Treatment for achondroplasia
JP5608097B2 (ja)	2008-01-08	2014-10-15	アレイバイオファーマ、インコーポレイテッド	キナーゼ阻害薬としてのピロロピリジン
JP5608098B2 (ja)	2008-01-09	2014-10-15	アレイバイオファーマ、インコーポレイテッド	キナーゼ阻害薬としてのピラゾロピリジン
CN101918079A (zh) *	2008-01-22	2010-12-15	默克专利有限公司	蛋白激酶抑制剂及其用途
WO2009106445A1 (en) *	2008-02-25	2009-09-03	F. Hoffmann-La Roche Ag	Pyrrolopyrazine kinase inhibitors
WO2009111280A1 (en)	2008-02-29	2009-09-11	Array Biopharma Inc.	N- (6-aminopyridin-3-yl) -3- (sulfonamido) benzamide derivatives as b-raf inhibitors for the treatment of cancer
TW200940539A (en)	2008-02-29	2009-10-01	Array Biopharma Inc	RAF inhibitor compounds and methods of use thereof
EP2265608A2 (en)	2008-02-29	2010-12-29	Array Biopharma, Inc.	Raf inhibitor compounds and methods of use thereof
UA103319C2 (en)	2008-05-06	2013-10-10	Глаксосмитклайн Ллк	Thiazole- and oxazole-benzene sulfonamide compounds
WO2009143018A2 (en)	2008-05-19	2009-11-26	Plexxikon, Inc.	Compounds and methods for kinase modulation, and indications therefor
PE20091846A1 (es)	2008-05-19	2009-12-16	Plexxikon Inc	DERIVADOS DE PIRROLO[2,3-d]-PIRIMIDINA COMO MODULADORES DE CINASAS
BRPI0912892A2 (pt) *	2008-05-21	2016-05-31	Basf Se	compostos, processo para a preparação de compostos, composições agroquímicas, método para combater fungos patogênicos, e, semente
BRPI0912109A2 (pt) *	2008-05-28	2015-07-28	Basf Se	Composto, processo para preparar os mesmos, composições agroquímicas, método para combater fungos nocivos fitopatogênicos, uso dos compostos, e, semente
WO2009152083A1 (en)	2008-06-10	2009-12-17	Plexxikon, Inc.	5h-pyrr0l0 [2,3-b] pyrazine derivatives for kinase modulation, and indications therefor
WO2009152087A1 (en)	2008-06-10	2009-12-17	Plexxikon, Inc.	Bicyclic heteroaryl compounds and methods for kinase modulation, and indications therefor
AR072008A1 (es) *	2008-06-13	2010-07-28	Merck & Co Inc	Compuestos heterobiciclicos como agentes de inhibicion de quinasa p38
US9447049B2 (en)	2010-03-01	2016-09-20	University Of Tennessee Research Foundation	Compounds for treatment of cancer
EP2298731A4 (en)	2008-06-25	2011-09-21	Takeda Pharmaceutical	AMIDE COMPOUND
EP3311818A3 (en)	2008-07-16	2018-07-18	Pharmacyclics, LLC	Inhibitors of bruton's tyrosine kinase for the treatment of solid tumors
DE102008052943A1 (de)	2008-10-23	2010-04-29	Merck Patent Gmbh	Azaindolderivate
EP2356116A1 (en) *	2008-11-20	2011-08-17	OSI Pharmaceuticals, Inc.	Substituted pyrroloý2,3-b¨-pyridines and-pyrazines
AU2009324894B2 (en) *	2008-11-25	2015-04-09	University Of Rochester	MLK inhibitors and methods of use
US8318446B2 (en) *	2008-12-05	2012-11-27	California Institute Of Technology	DNA-damage-induced proteolysis
EP2396321B1 (en) *	2009-02-10	2015-05-06	Monsanto Technology LLC	Compositions and methods for controlling nematodes
JP2012520311A (ja) *	2009-03-11	2012-09-06	プレキシコンインコーポレーテッド	Ｒａｆキナーゼの阻害のためのピロロ［２，３−ｂ］ピリジン誘導体
PE20120184A1 (es) *	2009-03-11	2012-03-28	Plexxikon Inc	Derivados del pirrolo[2,3-b]piridina para la inhibicion de las proteinas quinasas raf
WO2010111527A1 (en) *	2009-03-26	2010-09-30	Plexxikon, Inc.	Pyrazolo [ 3, 4 -b] pyridines as kinase inhibitors and their medical use
CR20170089A (es)	2009-04-03	2017-07-17	Plexxikon Inc	Composiciones del acido propano-1--sulfonico {3-[5-(4-cloro-fenil)-1h-pirrolo [2,3-b] piridina-3-carbonil] -2,4-difluoro-fenil}-amida y el uso de las mismas
TW201041888A (en)	2009-05-06	2010-12-01	Plexxikon Inc	Compounds and methods for kinase modulation, and indications therefor
EA025520B1 (ru)	2009-05-22	2017-01-30	Инсайт Холдингс Корпорейшн	N-(ГЕТЕРО)АРИЛПИРРОЛИДИНОВЫЕ ПРОИЗВОДНЫЕ ПИРАЗОЛ-4-ИЛ-ПИРРОЛО[2,3-d]ПИРИМИДИНОВ И ПИРРОЛ-3-ИЛ-ПИРРОЛО[2,3-d]ПИРИМИДИНОВ В КАЧЕСТВЕ ИНГИБИТОРОВ ЯНУС-КИНАЗЫ
MX2011012262A (es)	2009-05-22	2012-01-25	Incyte Corp	3-[4-(7h-pirrolo[2,3-d]pirimidin-4-il)-1h-pirazol-1-il] octano-o heptano-nitrilo como inhibidores de cinasas janus (jak).
US9034875B2 (en)	2009-05-26	2015-05-19	Abbvie Inc.	Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
PE20120345A1 (es)	2009-05-26	2012-05-17	Abbvie Bahamas Ltd	Derivados de 2-(1h-pirrolo[2,3-b]piridin-5-iloxi)-n-fenilsulfonilbenzamida como inhibidores de proteinas anti-apoptoticas
US8546399B2 (en) *	2009-05-26	2013-10-01	Abbvie Inc.	Apoptosis inducing agents for the treatment of cancer and immune and autoimmune diseases
US20220315555A1 (en)	2009-05-26	2022-10-06	Abbvie Inc.	Apoptosis inducing agents for the treatment of cancer and immune and autoimmune diseases
RS57869B1 (sr)	2009-06-17	2018-12-31	Vertex Pharma	Inhibitori replikacije virusa gripa
AR077468A1 (es)	2009-07-09	2011-08-31	Array Biopharma Inc	Compuestos de pirazolo (1,5 -a) pirimidina sustituidos como inhibidores de trk- quinasa
US8329724B2 (en)	2009-08-03	2012-12-11	Hoffmann-La Roche Inc.	Process for the manufacture of pharmaceutically active compounds
EP2470533A4 (en)	2009-08-24	2013-01-23	Ascepion Pharmaceuticals Inc	UREA COMPOUNDS CONTAINING A 5,6-BICYCLIC HETEROARYL GROUP
SG178900A1 (en)	2009-08-28	2012-04-27	Genentech Inc	Raf inhibitor compounds and methods of use thereof
CN102858754A (zh)	2009-08-28	2013-01-02	阵列生物制药公司	Raf抑制剂化合物及其使用方法
JP2013503188A (ja)	2009-08-28	2013-01-31	アレイバイオファーマ、インコーポレイテッド	Ｒａｆ阻害化合物およびその使用方法
CN102482283A (zh)	2009-08-28	2012-05-30	阵列生物制药公司	Raf抑制剂化合物及其使用方法
WO2011025947A1 (en)	2009-08-28	2011-03-03	Array Biopharma Inc.	Raf inhibitor compounds and methods of use thereof
WO2011025968A1 (en)	2009-08-28	2011-03-03	Array Biopharma Inc.	1h-pyrazolo [ 3, 4-b] pyridine compounds for inhibiting raf kinase
TW201113285A (en)	2009-09-01	2011-04-16	Incyte Corp	Heterocyclic derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors
WO2011050344A2 (en)	2009-10-23	2011-04-28	Mannkind Corporation	Cancer immunotherapy and method of treatment
NZ599866A (en) *	2009-11-06	2014-09-26	Plexxikon Inc	Compounds and methods for kinase modulation, and indications therefor
WO2011060216A1 (en)	2009-11-12	2011-05-19	Concert Pharmaceuticals Inc.	Substituted azaindoles
ES2627911T3 (es) *	2009-11-18	2017-08-01	Plexxikon, Inc.	Derivados de N-[2-fluoro-3-(4-amino-7H-pirrolo[2,3-d]pirimidin-5-carbonil)-fenil]-4-bencenosulfonamida como moduladores de la proteína quinasa Raf para el tratamiento del cáncer
DE102009058280A1 (de) *	2009-12-14	2011-06-16	Merck Patent Gmbh	Thiazolderivate
CN102753549A (zh) *	2009-12-23	2012-10-24	普莱希科公司	用于激酶调节的化合物和方法及其适应症
CA2784807C (en) *	2009-12-29	2021-12-14	Dana-Farber Cancer Institute, Inc.	Type ii raf kinase inhibitors
EP2521551A4 (en) *	2010-01-06	2013-08-21	Errico Joseph P	METHOD AND COMPOSITIONS FOR TARGETED ACTIVE DEVELOPMENT
US8658170B2 (en)	2010-01-06	2014-02-25	Joseph P. Errico	Combination therapy with MDM2 and EFGR inhibitors
JP5883399B2 (ja)	2010-02-11	2016-03-15	ヴァンダービルトユニバーシティーＶａｎｄｅｒｂｉｌｔＵｎｉｖｅｒｓｉｔｙ	ｍＧｌｕＲ４アロステリック増強剤としてのピラゾロピリジン、ピラゾロピラジン、ピラゾロピリミジン、ピラゾロチオフェンおよびピラゾロチアゾール化合物、組成物、および神経機能不全を治療する方法
US11084811B2 (en)	2010-03-01	2021-08-10	Oncternal Therapeutics, Inc.	Compounds for treatment of cancer
SI3354652T1 (sl)	2010-03-10	2020-08-31	Incyte Holdings Corporation	Derivati piperidin-4-il azetidina kot inhibitorji JAK1
WO2011119842A1 (en)	2010-03-25	2011-09-29	The J. David Gladstone Institutes	Compositions and methods for treating neurological disorders
CN102939282B (zh) *	2010-04-16	2015-12-02	Ac免疫有限公司	用于治疗与淀粉状蛋白或淀粉状蛋白样蛋白有关的疾病的化合物
TWI619713B (zh)	2010-04-21	2018-04-01	普雷辛肯公司	用於激酶調節的化合物和方法及其適應症
US20130059850A1 (en) *	2010-05-06	2013-03-07	Merck Sharp & Dohme Corp.	Aza-indole derivatives useful as modulators of faah
WO2011143646A1 (en)	2010-05-14	2011-11-17	OSI Pharmaceuticals, LLC	Fused bicyclic kinase inhibitors
AR081039A1 (es) *	2010-05-14	2012-05-30	Osi Pharmaceuticals Llc	Inhibidores biciclicos fusionados de quinasa
MX365251B (es)	2010-05-20	2019-05-28	Array Biopharma Inc	Compuestos macrocíclicos como inhibidores de trk cinasa.
SG10201910912TA (en)	2010-05-21	2020-01-30	Incyte Corp	Topical Formulation for a JAK Inhibitor
US8669256B2 (en)	2010-05-28	2014-03-11	Merck Sharp & Dohme B.V.	Substituted thieno[2,3-b]pyrazine compounds as modulators of B-Raf kinase activity
WO2011153514A2 (en)	2010-06-03	2011-12-08	Pharmacyclics, Inc.	The use of inhibitors of bruton's tyrosine kinase (btk)
AU2011264074B2 (en)	2010-06-09	2015-01-22	Bayer Cropscience Nv	Methods and means to modify a plant genome at a nucleotide sequence commonly used in plant genome engineering
US8779150B2 (en) *	2010-07-21	2014-07-15	Hoffmann-La Roche Inc.	Processes for the manufacture of propane-1-sulfonic acid {3-[5-(4-chloro-phenyl)-1 H-pyrrolo[2,3-b]pyridine-3-carbonyl]-2,4-difluoro-phenyl}-amide
WO2012018638A2 (en)	2010-07-26	2012-02-09	Biomatrica, Inc.	Compositions for stabilizing dna, rna and proteins in blood and other biological samples during shipping and storage at ambient temperatures
US9845489B2 (en)	2010-07-26	2017-12-19	Biomatrica, Inc.	Compositions for stabilizing DNA, RNA and proteins in saliva and other biological samples during shipping and storage at ambient temperatures
US20120045433A1 (en)	2010-08-17	2012-02-23	Kapil Dhingra	Combination therapy
US8709419B2 (en) *	2010-08-17	2014-04-29	Hoffmann-La Roche, Inc.	Combination therapy
WO2012037060A1 (en)	2010-09-13	2012-03-22	Concert Pharmaceuticals Inc.	Substituted azaindoles
UA113500C2 (xx)	2010-10-29	2017-02-10		Одержані екструзією розплаву тверді дисперсії, що містять індукуючий апоптоз засіб
KR20180059560A (ko)	2010-10-29	2018-06-04	애브비 인코포레이티드	아폽토시스―유도제를 포함하는 고체 분산체
KR101236731B1 (ko)	2010-11-02	2013-02-25	한국과학기술원	아자인돌 화합물, 이를 포함하는 ｐｉ３ｋ 저해제용 약학 조성물 및 ｐｉ３ｋ와 연관된 질환 치료용 약학 조성물
BR112013012502A2 (pt)	2010-11-19	2019-03-06	Incyte Corporation	pirrolopiridina ciclobutil substituída e derivados de pirrolopirimidina derivativos como inibidores de jak
US9034884B2 (en)	2010-11-19	2015-05-19	Incyte Corporation	Heterocyclic-substituted pyrrolopyridines and pyrrolopyrimidines as JAK inhibitors
RU2628560C2 (ru)	2010-11-23	2017-08-18	Эббви Инк.	Соли и кристаллические формы индуцирующего апоптоз агента
DK2642999T3 (en)	2010-11-23	2017-01-09	Abbvie Ireland Unlimited Co	METHODS OF TREATMENT FOR USING selectivity-VE BCL-2 INHIBITORS
US9296811B2 (en)	2010-12-02	2016-03-29	University of Pittsburgh—of the Commonwealth System of Higher Education	Methods for treating a tumor using an antibody that specifically binds HMW-MAA
US9295669B2 (en) *	2010-12-14	2016-03-29	Hoffman La-Roche Inc.	Combination therapy for proliferative disorders
KR20140014110A (ko)	2010-12-16	2014-02-05	버텍스 파마슈티칼스 인코포레이티드	인플루엔자 바이러스 복제의 억제제
JP2014505052A (ja)	2011-01-06	2014-02-27	ベータファルマカナダインコーポレーテッド	癌の治療および予防用の新規なウレア
MA34948B1 (fr) *	2011-02-07	2014-03-01	Plexxikon Inc	Composes et procedes de modulation de kinase, et leurs indications
EP2672963A4 (en)	2011-02-08	2015-06-24	Childrens Medical Center	METHOD FOR THE TREATMENT OF MELANOMA
WO2012112847A1 (en)	2011-02-18	2012-08-23	Novartis Pharma Ag	mTOR/JAK INHIBITOR COMBINATION THERAPY
TWI558702B (zh) *	2011-02-21	2016-11-21	普雷辛肯公司	醫藥活性物質的固態形式
US20140199292A1 (en) *	2011-03-15	2014-07-17	Inserm (Institut National De La Sante Et De La Recherche Medicale)	Compositions and methods for inhibiting tumor development caused by chemotherapy induced senescence
SG194048A1 (en) *	2011-04-01	2013-11-29	Genentech Inc	Combinations of akt inhibitor compounds and chemotherapeutic agents, and methods of use
WO2012138809A1 (en) *	2011-04-05	2012-10-11	Dawei Zhang	Heterocyclic compounds as kinase inhibitors
CA2828946C (en) *	2011-04-18	2016-06-21	Eisai R&D Management Co., Ltd.	Therapeutic agent for tumor
US9222137B2 (en) *	2011-05-10	2015-12-29	Trovagene, Inc.	Method for monitoring minimal residual hairy cell leukemia
US20140088114A1 (en)	2011-05-16	2014-03-27	OSI Pharmaceuticals ,LLC	Fused bicyclic kinase inhibitors
RU2631487C2 (ru)	2011-05-17	2017-09-22	Плексксикон Инк.	Модуляция киназ и показания к её применению
JP2014515368A (ja)	2011-05-26	2014-06-30	第一三共株式会社	プロテインキナーゼ阻害剤としての複素環化合物
ES2705950T3 (es)	2011-06-03	2019-03-27	Eisai R&D Man Co Ltd	Biomarcadores para predecir y valorar la capacidad de respuesta de sujetos con cáncer de tiroides y de riñón a compuestos de lenvatinib
WO2012170752A1 (en) *	2011-06-10	2012-12-13	Glaxo Wellcome Manufacturing Pte Ltd	Novel compounds
MY165963A (en)	2011-06-20	2018-05-18	Incyte Holdings Corp	Azetidinyl phenyl, pyridyl or pyrazinyl carboxamide derivatives as jak inhibitors
WO2013010136A2 (en)	2011-07-13	2013-01-17	Pharmacyclics, Inc.	Inhibitors of bruton's tyrosine kinase
TW201840336A (zh)	2011-08-01	2018-11-16	美商建南德克公司	利用pd-1軸結合拮抗劑及mek抑制劑治療癌症之方法
UA118010C2 (uk) *	2011-08-01	2018-11-12	Вертекс Фармасьютікалз Інкорпорейтед	Інгібітори реплікації вірусів грипу
EP2741747A1 (en)	2011-08-10	2014-06-18	Novartis Pharma AG	JAK P13K/mTOR COMBINATION THERAPY
TW201313721A (zh)	2011-08-18	2013-04-01	Incyte Corp	作為ｊａｋ抑制劑之環己基氮雜環丁烷衍生物
WO2013029043A1 (en) *	2011-08-25	2013-02-28	Reaction Biology Corp.	Selective kinase inhibitors
ES2725790T3 (es)	2011-08-26	2019-09-27	Neupharma Inc	Algunas entidades químicas, composiciones, y métodos
UA111854C2 (uk)	2011-09-07	2016-06-24	Інсайт Холдінгс Корпорейшн	Способи і проміжні сполуки для отримання інгібіторів jak
AU2012308238B2 (en)	2011-09-14	2017-05-25	Neupharma, Inc.	Certain chemical entities, compositions, and methods
EP2570127A1 (en)	2011-09-16	2013-03-20	Sanofi	Compositions and methods for treating cancer using PI3KB beta inhibitor and MAPK pathway inhibitor, including MEK and RAF inhibitors
MX2014002990A (es)	2011-09-19	2014-05-21	Genentech Inc	Tratamientos combinados que comprenden antagonistas de c-met y antagonistas de b-raf.
WO2013062945A1 (en) *	2011-10-24	2013-05-02	Glaxosmithkline Intellectual Property Development Limited	Chemical compounds
WO2013074986A1 (en)	2011-11-17	2013-05-23	Dana-Farber Cancer Institute, Inc.	Inhibitors of c-jun-n-terminal kinase (jnk)
US8377946B1 (en)	2011-12-30	2013-02-19	Pharmacyclics, Inc.	Pyrazolo[3,4-d]pyrimidine and pyrrolo[2,3-d]pyrimidine compounds as kinase inhibitors
DK2797888T3 (en)	2011-12-31	2016-09-19	Beigene Ltd	Fused tricyclic compounds as RAF kinase inhibitors
WO2013109142A1 (en)	2012-01-16	2013-07-25	Stichting Het Nederlands Kanker Instituut	Combined pdk and mapk/erk pathway inhibition in neoplasia
CN102603734A (zh) *	2012-01-19	2012-07-25	盛世泰科生物医药技术(苏州)有限公司	一种蛋白激酶抑制剂及其应用
WO2013112950A2 (en)	2012-01-25	2013-08-01	Neupharma, Inc.	Certain chemical entities, compositions, and methods
US9358235B2 (en)	2012-03-19	2016-06-07	Plexxikon Inc.	Kinase modulation, and indications therefor
US9216170B2 (en)	2012-03-19	2015-12-22	Hoffmann-La Roche Inc.	Combination therapy for proliferative disorders
WO2013148365A1 (en)	2012-03-28	2013-10-03	Neuropore Therapies, Inc.	Phenyl-urea and phenyl-carbamate derivatives as inhibitors of protein aggregation
CN104395311B (zh) *	2012-04-23	2017-04-19	基因泰克公司	制备化合物的中间体和方法
US9193733B2 (en)	2012-05-18	2015-11-24	Incyte Holdings Corporation	Piperidinylcyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as JAK inhibitors
US9181261B2 (en) *	2012-05-22	2015-11-10	Merck Sharp & Dohme Corp.	TrkA kinase inhibitors, compositions and methods thereof
US10077474B2 (en) *	2012-05-29	2018-09-18	Abbott Molecular, Inc.	Method of designing primers, method of detecting single nucleotide polymorphisms (SNPs), method of distinguishing SNPs, and related primers, detectable oligonucleotides, and kits
CN104507933B (zh)	2012-05-31	2017-10-31	霍夫曼-拉罗奇有限公司	氨基喹唑啉和吡啶并嘧啶衍生物
US9150570B2 (en) *	2012-05-31	2015-10-06	Plexxikon Inc.	Synthesis of heterocyclic compounds
NZ702548A (en)	2012-06-04	2015-11-27	Pharmacyclics Llc	Crystalline forms of a bruton’s tyrosine kinase inhibitor
EP2870154A1 (en)	2012-07-03	2015-05-13	Ratiopharm GmbH	Solid state form of vemurafenib choline salt
JP6575950B2 (ja)	2012-07-24	2019-09-18	ファーマサイクリックスエルエルシー	Ｂｒｕｔｏｎ型チロシンキナーゼ（Ｂｔｋ）阻害剤に対する耐性を伴う変異
WO2014024077A1 (en) *	2012-08-07	2014-02-13	Aurigene Discovery Technologies Limited	5-(1H-PYRAZOL-4-YL)-1H-PYRROLO[2,3-b]PYRIDINE DERIVATIVES AS KINASE INHIBITORS
KR20150038068A (ko)	2012-08-17	2015-04-08	에프. 호프만-라 로슈 아게	코비메티닙 및 베무라피닙을 투여함을 포함하는 흑색종의 조합 치료법
TWI601725B (zh)	2012-08-27	2017-10-11	加拓科學公司	取代的氮雜吲哚化合物及其鹽、組合物和用途
CN103626765B (zh) *	2012-08-27	2016-08-10	广东东阳光药业有限公司	取代的氮杂吲哚化合物及其盐、组合物和用途
JP6318156B2 (ja)	2012-09-06	2018-04-25	プレキシコンインコーポレーテッドＰｌｅｘｘｉｋｏｎＩｎｃ．	キナーゼをモジュレートするための化合物および方法、ならびにその指標
CN104812389B (zh)	2012-09-24	2020-07-17	润新生物公司	某些化学实体、组合物及方法
CN103613591B (zh) *	2012-09-29	2016-04-13	上海科州药物研发有限公司	作为cMet抑制剂的化合物及其制备方法和用途
JP2015531395A (ja)	2012-10-04	2015-11-02	ファイザー・リミテッドＰｆｉｚｅｒＬｉｍｉｔｅｄ	ピロロ［３，２−ｃ］ピリジントロポミオシン関連キナーゼ阻害剤
JP6294889B2 (ja) *	2012-10-08	2018-03-14	アトリバセラピューティクスゲーエムベーハー	ウイルス疾患の処置におけるｍｅｋ阻害物質
US10112927B2 (en)	2012-10-18	2018-10-30	Dana-Farber Cancer Institute, Inc.	Inhibitors of cyclin-dependent kinase 7 (CDK7)
WO2014063054A1 (en)	2012-10-19	2014-04-24	Dana-Farber Cancer Institute, Inc.	Bone marrow on x chromosome kinase (bmx) inhibitors and uses thereof
WO2014063061A1 (en)	2012-10-19	2014-04-24	Dana-Farber Cancer Institute, Inc.	Hydrophobically tagged small molecules as inducers of protein degradation
EP2916838B1 (en)	2012-11-12	2019-03-13	Neupharma, Inc.	Certain chemical entities, compositions, and methods
SG11201503695XA (en)	2012-11-15	2015-06-29	Incyte Corp	Sustained-release dosage forms of ruxolitinib
MX2015006168A (es)	2012-11-15	2015-08-10	Pharmacyclics Inc	Compuestos de pirrolopirimidina como inhibidores de quinasas.
US9260426B2 (en) *	2012-12-14	2016-02-16	Arrien Pharmaceuticals Llc	Substituted 1H-pyrrolo [2, 3-b] pyridine and 1H-pyrazolo [3, 4-b] pyridine derivatives as salt inducible kinase 2 (SIK2) inhibitors
WO2014100755A2 (en)	2012-12-20	2014-06-26	Biomatrica, Inc.	Formulations and methods for stabilizing pcr reagents
PL2935248T3 (pl)	2012-12-21	2018-07-31	Plexxikon Inc	Związki i sposoby modulacji kinaz i wskazania dla nich
CN104755463A (zh)	2012-12-21	2015-07-01	卫材R&D管理有限公司	非晶态形式的喹啉衍生物及其生产方法
JP6437452B2 (ja)	2013-01-14	2018-12-12	インサイト・ホールディングス・コーポレイションＩｎｃｙｔｅＨｏｌｄｉｎｇｓＣｏｒｐｏｒａｔｉｏｎ	Ｐｉｍキナーゼ阻害剤として有用な二環式芳香族カルボキサミド化合物
ME03780B (me)	2013-01-15	2021-04-20	Incyte Holdings Corp	Jedinjenja tiazolkarboksamida i piridinkarboksamida korisna kao inhibitori pim kinaze
US20140357636A1 (en) *	2013-02-21	2014-12-04	Wayne Rothbaum	Treatment of Skeletal-Related Disorders
JP2016509045A (ja)	2013-02-22	2016-03-24	エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト	がんを治療し、薬剤耐性を防止する方法
CN109568312A (zh) *	2013-03-05	2019-04-05	田纳西大学研究基金会	用于治疗癌症的化合物
EA030705B1 (ru)	2013-03-06	2018-09-28	Инсайт Холдингс Корпорейшн	Способы и промежуточные соединения при получении ингибитора jak
US20140275082A1 (en)	2013-03-14	2014-09-18	Abbvie Inc.	Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
US9440971B2 (en)	2013-03-14	2016-09-13	Ratiopharm Gmbh	Solid state forms of vemurafenib hydrochloride
MX2015011899A (es)	2013-03-15	2016-05-05	Genentech Inc	Metodos para el tratamiento de cáncer y prevención de resistencia a los fármacos para el cáncer.
CA2904770A1 (en)	2013-03-15	2014-09-18	Sanofi	Anti-tumoral composition comprising a pi3kbeta inhibitor and a raf inhibitor, to overcome cancer cells resistance
CA2903293C (en)	2013-03-15	2020-10-13	Plexxikon Inc.	Heterocyclic compounds and uses thereof
US20140303121A1 (en)	2013-03-15	2014-10-09	Plexxikon Inc.	Heterocyclic compounds and uses thereof
US9206188B2 (en) *	2013-04-18	2015-12-08	Arrien Pharmaceuticals Llc	Substituted pyrrolo[2,3-b]pyridines as ITK and JAK inhibitors
MX368099B (es)	2013-05-14	2019-09-19	Eisai R&D Man Co Ltd	Biomarcadores para predecir y evaluar el grado de respuesta de sujetos con cancer de endometrio a compuestos de tipo lenvatinib.
CA2912568A1 (en)	2013-05-30	2014-12-04	Plexxikon Inc.	Compounds for kinase modulation, and indications therefor
CA2915250A1 (en)	2013-06-13	2015-01-08	Biomatrica, Inc.	Cell stabilization
WO2014206344A1 (en)	2013-06-28	2014-12-31	Beigene, Ltd.	Fused tricyclic amide compounds as multiple kinase inhibitors
CA2917742C (en) *	2013-07-12	2020-04-14	Piramal Enterprises Limited	A pharmaceutical combination for the treatment of melanoma
JP6800750B2 (ja)	2013-08-02	2020-12-16	ファーマサイクリックスエルエルシー	固形腫瘍の処置方法
ES2792549T3 (es)	2013-08-07	2020-11-11	Incyte Corp	Formas de dosificación de liberación sostenida para un inhibidor de JAK1
CA2920534A1 (en)	2013-08-12	2015-02-19	Pharmacyclics Llc	Methods for the treatment of her2 amplified cancer
WO2015027124A1 (en)	2013-08-23	2015-02-26	Incyte Corporation	Furo- and thieno-pyridine carboxamide compounds useful as pim kinase inhibitors
WO2015041534A1 (en)	2013-09-20	2015-03-26	Stichting Het Nederlands Kanker Instituut	P90rsk in combination with raf/erk/mek
WO2015041533A1 (en)	2013-09-20	2015-03-26	Stichting Het Nederlands Kanker Instituut	Rock in combination with mapk-pathway
PE20160560A1 (es)	2013-09-30	2016-06-09	Pharmacyclics Llc	DERIVADOS DE PIRAZOLO[3,4-d]PIRIMIDIN COMO INHIBIDORES IRREVERSIBLES DE LA TIROSINA CINASA DE BRUTON (BTK)
JP6491202B2 (ja)	2013-10-18	2019-03-27	デイナファーバーキャンサーインスティチュート，インコーポレイテッド	サイクリン依存性キナーゼ７（ｃｄｋ７）の多環阻害剤
ES2676734T3 (es)	2013-10-18	2018-07-24	Syros Pharmaceuticals, Inc.	Compuestos heteroatómicos útiles para el tratamiento de enfermedades proliferativas
SI3068782T1 (sl)	2013-11-13	2018-10-30	Vertex Pharmaceuticals Incorporated	Postopki za pripravo inhibitorjev v replikacije virusov gripe
JP6615755B2 (ja)	2013-11-13	2019-12-04	バーテックスファーマシューティカルズインコーポレイテッド	インフルエンザウイルスの複製の阻害剤
MX2016006325A (es) *	2013-11-15	2016-12-02	Wistar Inst	Inhibidores del antígeno nuclear 1 de epstein-barr, y su método de uso.
WO2015075749A1 (en) *	2013-11-22	2015-05-28	Laurus Labs Private Limited	Novel processes for the preparation of vemurafenib
CZ2013943A3 (cs)	2013-11-27	2015-06-03	Zentiva, K.S.	Krystalické formy vemurafenibu
CN104710417B (zh) *	2013-12-11	2020-09-08	上海科州药物研发有限公司	氮杂吲哚类衍生物及其合成方法
BR112016014481B1 (pt) *	2013-12-20	2022-11-08	Biomed Valley Discoveries, Inc	Uso de uma composição farmacêutica, método in vitro para efetuar a morte de células cancerosas, e kit
CN104739823A (zh) *	2013-12-28	2015-07-01	复旦大学附属华山医院	淫羊藿素在制备维罗非尼增敏剂中的用途
WO2015134536A1 (en)	2014-03-04	2015-09-11	Plexxikon Inc.	Compounds and methods for kinase modulation, and indications therefor
US9885086B2 (en)	2014-03-20	2018-02-06	Pharmacyclics Llc	Phospholipase C gamma 2 and resistance associated mutations
WO2015156674A2 (en)	2014-04-10	2015-10-15	Stichting Het Nederlands Kanker Instituut	Method for treating cancer
US9862688B2 (en)	2014-04-23	2018-01-09	Dana-Farber Cancer Institute, Inc.	Hydrophobically tagged janus kinase inhibitors and uses thereof
US10017477B2 (en)	2014-04-23	2018-07-10	Dana-Farber Cancer Institute, Inc.	Janus kinase inhibitors and uses thereof
JP2017514866A (ja) *	2014-05-06	2017-06-08	ザリージェンツオブザユニバーシティオブカリフォルニア	Ｂｒａｆ阻害剤を使用する創傷治癒
WO2015178770A1 (en)	2014-05-19	2015-11-26	Stichting Het Nederlands Kanker Instituut	Compositions for cancer treatment
WO2015181628A1 (en) *	2014-05-27	2015-12-03	Eisai R&D Management Co., Ltd.	Treatment of acute myeloid leukemia with an hck inhibitor
WO2015184305A1 (en)	2014-05-30	2015-12-03	Incyte Corporation	TREATMENT OF CHRONIC NEUTROPHILIC LEUKEMIA (CNL) AND ATYPICAL CHRONIC MYELOID LEUKEMIA (aCML) BY INHIBITORS OF JAK1
TW201613916A (en)	2014-06-03	2016-04-16	Gilead Sciences Inc	TANK-binding kinase inhibitor compounds
ES2786373T3 (es)	2014-06-10	2020-10-09	Biomatrica Inc	Estabilización de trombocitos a temperaturas ambiente
WO2015191996A1 (en) *	2014-06-13	2015-12-17	Genentech, Inc.	Methods of treating and preventing cancer drug resistance
JP2017517552A (ja)	2014-06-13	2017-06-29	ジェネンテック，インコーポレイテッド	抗癌剤耐性の治療及び防止方法
WO2016000615A1 (en) *	2014-07-02	2016-01-07	Sunshine Lake Pharma Co., Ltd.	Heteroaryl compounds and pharmaceutical applications thereof
TW201613919A (en)	2014-07-02	2016-04-16	Pharmacyclics Llc	Inhibitors of Bruton's tyrosine kinase
US9822124B2 (en)	2014-07-14	2017-11-21	Incyte Corporation	Bicyclic heteroaromatic carboxamide compounds useful as Pim kinase inhibitors
US9580418B2 (en)	2014-07-14	2017-02-28	Incyte Corporation	Bicyclic aromatic carboxamide compounds useful as Pim kinase inhibitors
AU2015289672A1 (en)	2014-07-15	2017-03-02	Genentech, Inc.	Compositions for treating cancer using PD-1 axis binding antagonists and MEK inhibitors
US9533991B2 (en)	2014-08-01	2017-01-03	Pharmacyclics Llc	Inhibitors of Bruton's tyrosine kinase
JP2017523206A (ja)	2014-08-07	2017-08-17	ファーマサイクリックスエルエルシー	ブルトン型チロシンキナーゼ阻害剤の新規製剤
JO3783B1 (ar)	2014-08-28	2021-01-31	Eisai R&D Man Co Ltd	مشتق كوينولين عالي النقاء وطريقة لإنتاجه
JP6832846B2 (ja)	2014-09-15	2021-02-24	プレキシコンインコーポレーテッドＰｌｅｘｘｉｋｏｎＩｎｃ．	ヘテロ環化合物およびその用途
ES2727376T3 (es)	2014-09-26	2019-10-15	Gilead Sciences Inc	Derivados de aminotriazina útiles como compuestos inhibidores de quinasa de unión TANK
AU2015328411C1 (en)	2014-10-06	2022-03-03	Dana-Farber Cancer Institute, Inc.	Angiopoietin-2 biomarkers predictive of anti-immune checkpoint response
WO2016073771A2 (en) *	2014-11-06	2016-05-12	Ohio State Innovation Foundation	Pyrrolopyrimidine derivatives as mps1/ttk kinase inhibitors
WO2016083956A1 (en) *	2014-11-29	2016-06-02	Shilpa Medicare Limited	Substantially pure vemurafenib and its salts
WO2016105528A2 (en)	2014-12-23	2016-06-30	Dana-Farber Cancer Institute, Inc.	Inhibitors of cyclin-dependent kinase 7 (cdk7)
US9694084B2 (en)	2014-12-23	2017-07-04	Dana-Farber Cancer Institute, Inc.	Methods to induce targeted protein degradation through bifunctional molecules
WO2016105518A1 (en) *	2014-12-23	2016-06-30	Dana-Farber Cancer Institute, Inc.	Methods to induce targeted protein degradation through bifunctional molecules
DK3263106T3 (da)	2015-02-25	2024-01-08	Eisai R&D Man Co Ltd	Fremgangsmåde til undertrykkelse af bitterhed af quinolinderivat
BR122023020985A2 (pt)	2015-03-03	2023-12-26	Pharmacyclics Llc	Formulação de comprimido sólido de um inibidor de tirosina quinase de bruton
CA2978226A1 (en)	2015-03-04	2016-09-09	Merck Sharpe & Dohme Corp.	Combination of a pd-1 antagonist and a vegfr/fgfr/ret tyrosine kinase inhibitor for treating cancer
CA2978518C (en)	2015-03-27	2023-11-21	Nathanael S. Gray	Inhibitors of cyclin-dependent kinases
WO2016164641A1 (en)	2015-04-08	2016-10-13	Plexxikon Inc.	Compounds and methods for kinase modulation, and indications therefor
CZ2015250A3 (cs)	2015-04-14	2016-10-26	Zentiva, K.S.	Amorfní formy vemurafenibu
CN107531706A (zh)	2015-05-06	2018-01-02	普莱希科公司	调节激酶的1H‑吡咯并[2,3‑b]吡啶衍生物的合成
WO2016179415A1 (en)	2015-05-06	2016-11-10	Plexxikon Inc.	Solid forms of a compound modulating kinases
EP3294717B1 (en)	2015-05-13	2020-07-29	Vertex Pharmaceuticals Inc.	Methods of preparing inhibitors of influenza viruses replication
JP6857617B2 (ja)	2015-05-13	2021-04-14	バーテックスファーマシューティカルズインコーポレイテッドＶｅｒｔｅｘＰｈａｒｍａｃｅｕｔｉｃａｌｓＩｎｃｏｒｐｏｒａｔｅｄ	インフルエンザウイルスの複製の阻害剤
CN107848964B (zh)	2015-05-14	2021-03-19	威斯塔解剖学和生物学研究所	Ebna1抑制剂和使用其的方法
CA2986739C (en)	2015-05-22	2023-03-14	Plexxikon Inc.	Plx-8394 or plx-7904 for use in the treatment of braf-v600-related diseases
HUE050936T2 (hu)	2015-05-22	2021-01-28	Plexxikon Inc	Heterociklusos vegyületek szintézise
US9540347B2 (en)	2015-05-29	2017-01-10	Incyte Corporation	Pyridineamine compounds useful as Pim kinase inhibitors
JP6549735B2 (ja) *	2015-06-09	2019-07-24	アッヴィ・インコーポレイテッド	核内受容体調節剤
EP3307728A4 (en)	2015-06-12	2019-07-17	Dana Farber Cancer Institute, Inc.	ASSOCIATION THERAPY USING TRANSCRIPTION INHIBITORS AND KINASE INHIBITORS
CN107801379B (zh)	2015-06-16	2021-05-25	卫材R&D管理有限公司	抗癌剂
PL3322706T3 (pl)	2015-07-16	2021-07-19	Array Biopharma, Inc.	Podstawione związki pirazolo[1,5-a]pirydynowe jako inhibitory kinazy ret
CA3217238A1 (en) *	2015-07-20	2017-01-26	Genzyme Corporation	Colony stimulating factor-1 receptor (csf-1r) inhibitors
US10829484B2 (en)	2015-07-28	2020-11-10	Plexxikon Inc.	Compounds and methods for kinase modulation, and indications therefor
EP3328372A4 (en)	2015-07-28	2019-03-20	University Of Iowa Research Foundation	COMPOSITIONS AND METHODS OF TREATING CANCER
AR105967A1 (es)	2015-09-09	2017-11-29	Incyte Corp	Sales de un inhibidor de pim quinasa
EP4019515A1 (en)	2015-09-09	2022-06-29	Dana-Farber Cancer Institute, Inc.	Inhibitors of cyclin-dependent kinases
TWI732785B (zh)	2015-09-21	2021-07-11	美商普雷辛肯公司	雜環化合物及其用途
TW201718546A (zh)	2015-10-02	2017-06-01	英塞特公司	適用作pim激酶抑制劑之雜環化合物
US9890163B2 (en)	2015-10-15	2018-02-13	Princeton Drug Discovery Inc	Inhibitors of protein kinases
CA3003153A1 (en)	2015-10-26	2017-05-04	Loxo Oncology, Inc.	Point mutations in trk inhibitor-resistant cancer and methods relating to the same
PL3377107T3 (pl)	2015-11-19	2020-12-14	F. Hoffmann-La Roche Ag	Sposoby leczenia nowotworu przy użyciu inhibitorów b-raf i inhibitorów immunologicznego punktu kontrolnego
SG11201804711RA (en)	2015-12-07	2018-07-30	Plexxikon Inc	Compounds and methods for kinase modulation, and indications therefor
ES2946184T3 (es)	2015-12-08	2023-07-13	Biomatrica Inc	Reducción de la velocidad de eritrosedimentación
RU2018120366A (ru)	2015-12-14	2020-01-16	Рэд.Ком, Ллс	Модульные цифровая камера и сотовый телефон
CU20180059A7 (es)	2015-12-17	2018-10-04	Gilead Sciences Inc	Compuestos inhibidores de la quinasa de unión a tank
CN109195957A (zh) *	2016-02-25	2019-01-11	塔克西斯医药股份有限公司	合成方法和中间体
WO2017161045A1 (en)	2016-03-16	2017-09-21	Plexxikon Inc.	Compounds and methods for kinase modulation and indications therefore
PE20181888A1 (es)	2016-04-04	2018-12-11	Loxo Oncology Inc	Formulaciones liquidas de (s)-n-(5-((r)-2-(2,5-difluorofenil)-pirrolidin-1-il)-pirazolo[1,5-a]pirimidin-3-il)-3-hidroxipirrolidina-1-carboxamida
US10045991B2 (en)	2016-04-04	2018-08-14	Loxo Oncology, Inc.	Methods of treating pediatric cancers
KR20210010652A (ko)	2016-04-04	2021-01-27	록쏘 온콜로지, 인코포레이티드	소아암을 치료하는 방법
CN109072311A (zh)	2016-04-15	2018-12-21	豪夫迈·罗氏有限公司	用于癌症的诊断和治疗方法
RU2745953C2 (ru)	2016-05-18	2021-04-05	Локсо Онколоджи, Инк.	Способ получения (s)-n-(5-((r)-2-(2,5-дифторфенил)пирролидин-1-ил)-пиразоло[1,5-a]пиримидин-3-ил)-3-гидроксипирролидин-1-карбоксамида и его солей
ES2895749T3 (es) *	2016-06-13	2022-02-22	Chemocentryx Inc	Métodos de tratamiento del cáncer pancreático
US11179484B2 (en)	2016-06-24	2021-11-23	University Of Iowa Research Foundation	Compositions and methods of treating melanoma
CA3029361A1 (en)	2016-07-01	2018-01-04	Fermion Oy	New processes for the preparation of vemurafenib
KR20230156174A (ko)	2016-07-12	2023-11-13	레볼루션 메디슨즈, 인크.	다른자리 입체성 shp2 억제제로서의 2,5-이치환 3-메틸 피라진 및 2,5,6-3치환 3-메틸 피라진
CN109715631B (zh) *	2016-09-16	2022-02-18	德国亥姆霍兹慕尼黑中心健康与环境研究中心（有限公司）	Traf 6抑制剂
TW201815766A (zh)	2016-09-22	2018-05-01	美商普雷辛肯公司	用於ｉｄｏ及ｔｄｏ調節之化合物及方法以及其適應症
JOP20190077A1 (ar)	2016-10-10	2019-04-09	Array Biopharma Inc	مركبات بيرازولو [1، 5-a]بيريدين بها استبدال كمثبطات كيناز ret
TWI704148B (zh)	2016-10-10	2020-09-11	美商亞雷生物製藥股份有限公司	作為ｒｅｔ激酶抑制劑之經取代吡唑并[1,5-a]吡啶化合物
EP3308773A1 (en)	2016-10-11	2018-04-18	Recordati Industria Chimica E Farmaceutica SPA	Formulations of cysteamine and cysteamine derivatives
AU2017345574A1 (en)	2016-10-19	2019-05-23	United States Government As Represented By The Department Of Veterans Affairs	Compositions and methods for treating cancer
JOP20190092A1 (ar)	2016-10-26	2019-04-25	Array Biopharma Inc	عملية لتحضير مركبات بيرازولو[1، 5-a]بيريميدين وأملاح منها
IL294410B2 (en)	2016-11-23	2024-02-01	Chemocentryx Inc	A method for the treatment of focal segmental tuberous sclerosis
JP2020501503A (ja)	2016-12-15	2020-01-23	ソシエテ・デ・プロデュイ・ネスレ・エス・アー	コンパニオンアニマルにおけるリン又は酵素を調節する組成物及び方法
US11173211B2 (en)	2016-12-23	2021-11-16	Arvinas Operations, Inc.	Compounds and methods for the targeted degradation of rapidly accelerated Fibrosarcoma polypeptides
AU2017395023B2 (en)	2016-12-23	2022-04-07	Plexxikon Inc.	Compounds and methods for CDK8 modulation and indications therefor
MX2019007649A (es)	2016-12-23	2019-09-10	Arvinas Operations Inc	Compuestos y metodos para la degradacion dirigida de polipeptidos de fibrosarcoma acelerado rapidamente.
MX2019008458A (es) *	2017-01-17	2019-12-02	Heparegenix Gmbh	Inhibidores de proteina cinasa para promover la regeneracion hepatica o reducir o prevenir la muerte de hepatocitos.
WO2018136663A1 (en)	2017-01-18	2018-07-26	Array Biopharma, Inc.	Ret inhibitors
WO2018136661A1 (en)	2017-01-18	2018-07-26	Andrews Steven W	SUBSTITUTED PYRAZOLO[1,5-a]PYRAZINE COMPOUNDS AS RET KINASE INHIBITORS
AU2018210196B2 (en)	2017-01-23	2022-06-02	Revolution Medicines, Inc.	Pyridine compounds as allosteric SHP2 inhibitors
CN110446709B (zh)	2017-01-23	2023-09-12	锐新医药公司	作为变构shp2抑制剂的二环化合物
US11471538B2 (en)	2017-02-10	2022-10-18	INSERM (Institut National de la Santéet de la Recherche Medicale)	Methods and pharmaceutical compositions for the treatment of cancers associated with activation of the MAPK pathway
JOP20190213A1 (ar)	2017-03-16	2019-09-16	Array Biopharma Inc	مركبات حلقية ضخمة كمثبطات لكيناز ros1
US11555031B2 (en)	2017-03-20	2023-01-17	The Broad Institute, Inc.	Compounds and methods for regulating insulin secretion
US10577366B2 (en)	2017-03-20	2020-03-03	Plexxikon Inc.	Crystalline forms of a compound that inhibits bromodomain
EP3600302A4 (en) *	2017-03-29	2020-12-30	United States Government as Represented by The Department of Veterans Affairs	METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER
WO2018183917A1 (en)	2017-03-30	2018-10-04	Taxis Pharmaceuticals, Inc.	Synthetic processes and synthetic intermediates
WO2018200981A1 (en) *	2017-04-28	2018-11-01	Quartz Therapeutics, Inc.	Raf-degrading conjugate compounds
WO2018210661A1 (en) *	2017-05-15	2018-11-22	Basf Se	Heteroaryl compounds as agrochemical fungicides
JP7212956B2 (ja) *	2017-05-19	2023-01-26	エヌフレクションセラピューティクスインコーポレイテッド	皮膚障害の処置用のピロロピリジン－アニリン化合物
MA49140A (fr)	2017-05-19	2020-03-25	Nflection Therapeutics Inc	Composés hétéroaromatiques-aniline fusionnés pour le traitement de troubles dermiques
WO2018226846A1 (en)	2017-06-07	2018-12-13	Plexxikon Inc.	Compounds and methods for kinase modulation
CN110944634A (zh)	2017-06-30	2020-03-31	加利福尼亚大学董事会	用于调节毛发生长的组合物和方法
TWI805599B (zh)	2017-07-25	2023-06-21	美商第一三共公司	激酶調節化合物之調配物
CN109384785B (zh) *	2017-08-10	2021-09-28	浙江海正药业股份有限公司	吡咯并吡啶酮类衍生物、其制备方法及其在医药上的用途
CA3073073A1 (en)	2017-09-08	2019-03-14	F. Hoffmann-La Roche Ag	Diagnostic and therapeutic methods for cancer
TWI812649B (zh)	2017-10-10	2023-08-21	美商絡速藥業公司	6-(2-羥基-2-甲基丙氧基)-4-(6-(6-((6-甲氧基吡啶-3-基)甲基)-3,6-二氮雜雙環[3.1.1]庚-3-基)吡啶-3-基)吡唑并[1,5-a]吡啶-3-甲腈之調配物
TWI791053B (zh)	2017-10-10	2023-02-01	美商亞雷生物製藥股份有限公司	6-(2-羥基-2-甲基丙氧基)-4-(6-(6-((6-甲氧基吡啶-3-基)甲基)-3,6-二氮雜雙環[3.1.1]庚-3-基)吡啶-3-基)吡唑并[1,5-a]吡啶-3-甲腈之結晶形式及其醫藥組合物
AU2018347361A1 (en)	2017-10-11	2020-04-30	Chemocentryx, Inc.	Treatment of focal segmental glomerulosclerosis with CCR2 antagonists
RU2020115095A (ru)	2017-10-12	2021-11-12	Революшн Медсинз, Инк.	Пиридиновые, пиразиновые и триазиновые соединения в качестве аллостерических ингибиторов shp2
CN111194318B (zh)	2017-10-13	2023-06-09	Opna生物公司	用于调节激酶的化合物固体形式
EP4245758A3 (en)	2017-10-26	2023-12-20	Xynomic Pharmaceuticals, Inc.	Crystalline salts of a b-raf kinase inhibitor
JP7175309B2 (ja)	2017-10-27	2022-11-18	プレキシコンインコーポレーテッド	キナーゼを調節する化合物の製剤
US10596161B2 (en)	2017-12-08	2020-03-24	Incyte Corporation	Low dose combination therapy for treatment of myeloproliferative neoplasms
RU2020123241A (ru)	2017-12-15	2022-01-17	Революшн Медсинз, Инк.	Полициклические соединения в качестве аллостерических ингибиторов shp2
EP3732285A1 (en)	2017-12-28	2020-11-04	Tract Pharmaceuticals, Inc.	Stem cell culture systems for columnar epithelial stem cells, and uses related thereto
TW201932464A (zh)	2018-01-18	2019-08-16	美商亞雷生物製藥股份有限公司	作為ret激酶抑制劑之經取代吡唑基[4,3-c]吡啶化合物
TWI802635B (zh)	2018-01-18	2023-05-21	美商亞雷生物製藥股份有限公司	作為ｒｅｔ激酶抑制劑之經取代吡咯并[2,3-d]嘧啶化合物
US11524963B2 (en)	2018-01-18	2022-12-13	Array Biopharma Inc.	Substituted pyrazolo[3,4-d]pyrimidines as RET kinase inhibitors
PL3746429T3 (pl)	2018-01-30	2022-06-20	Incyte Corporation	Procesy do otrzymywania (1-(3-fluoro-2-(trifluorometylo)izonikotynoilo)piperydyn-4-onu)
AU2019216264B2 (en)	2018-01-31	2023-08-31	Heparegenix Gmbh	Protein kinase MKK4 inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death
WO2019158579A1 (en)	2018-02-13	2019-08-22	Vib Vzw	Targeting minimal residual disease in cancer with rxr antagonists
CN112119072A (zh)	2018-03-20	2020-12-22	普莱希科公司	用于ido和tdo调节的化合物和方法，以及其适应症
WO2019191684A1 (en)	2018-03-30	2019-10-03	Incyte Corporation	Treatment of hidradenitis suppurativa using jak inhibitors
CA3095934A1 (en)	2018-04-05	2019-10-10	Beth Israel Deaconess Medical Center, Inc.	Aryl hydrocarbon receptor modulators and uses thereof
EP3560516A1 (en) *	2018-04-27	2019-10-30	Bergen Teknologioverforing AS	Combination therapy including beta-sitosterol in combination with at least one of a braf inhibitor, a mek inhibitor or an erk inhibitor and methods and use thereof
TW201946919A (zh)	2018-05-17	2019-12-16	威斯塔研究所	Ebna1抑制劑晶形、其製備方法及其使用方法
GB201808321D0 (en) *	2018-05-21	2018-07-11	Univ College Dublin Nat Univ Ireland Dublin	Compositions and uses thereof
RU2687107C1 (ru) *	2018-06-18	2019-05-07	федеральное государственное автономное образовательное учреждение высшего образования "Московский физико-технический институт (государственный университет)"	Ингибитор braf киназы n-(3-(5-(4-хлорофенил)-1h-пиразоло[3,4-b]пиридин-3-карбонил)-2,4-дифторофенил) пропан-1-сульфонамид
EP3810139A1 (en)	2018-06-21	2021-04-28	HepaRegeniX GmbH	Tricyclic protein kinase inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death
CA3105747A1 (en) *	2018-07-06	2020-01-09	The Regents Of The University Of Colorado, A Body Corporate	Genetically encoded system for constructing and detecting biologically active agents
CA3104246A1 (en)	2018-07-16	2020-01-23	Heparegenix Gmbh	Protein kinase inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death
WO2020015744A1 (zh) *	2018-07-19	2020-01-23	南京明德新药研发有限公司	氮杂吲哚衍生物及其作为FGFR和C-Met抑制剂的应用
KR102653681B1 (ko)	2018-07-31	2024-04-03	록쏘 온콜로지, 인코포레이티드	(s)-5-아미노-3-(4-((5-플루오로-2-메톡시벤즈아미도)메틸)페닐)-1-(1,1,1-트리플루오로프로판-2-일)-1h-피라졸-4-카르복스아미드의분무-건조된 분산물 및 제제
ES2922314T3 (es)	2018-09-10	2022-09-13	Array Biopharma Inc	Compuestos heterocíclicos condensados como inhibidores de cinasa RET
WO2020070390A1 (en)	2018-10-03	2020-04-09	Jyväskylän Yliopisto	Vemurafenib and salts thereof for use in the treatment of enteroviral infections
US11066404B2 (en)	2018-10-11	2021-07-20	Incyte Corporation	Dihydropyrido[2,3-d]pyrimidinone compounds as CDK2 inhibitors
EP3867409A1 (en)	2018-10-16	2021-08-25	Novartis AG	Tumor mutation burden alone or in combination with immune markers as biomarkers for predicting response to targeted therapy
CN113423707A (zh) *	2018-11-16	2021-09-21	加利福尼亚技术学院	Erk抑制剂及其用途
US11572344B2 (en)	2018-11-20	2023-02-07	Nflection Therapeutics, Inc.	Cyanoaryl-aniline compounds for treatment of dermal disorders
CN113166097A (zh) *	2018-12-03	2021-07-23	默克专利股份公司	作为端锚聚合酶抑制剂的4-杂芳基羰基-n-(苯基或杂芳基)哌啶-1-甲酰胺
CN113490666A (zh)	2018-12-19	2021-10-08	奥瑞生物药品公司	作为fgfr酪氨酸激酶的抑制剂的取代的吡唑并[1,5-a]吡啶化合物
EP3898615A1 (en)	2018-12-19	2021-10-27	Array Biopharma, Inc.	7-((3,5-dimethoxyphenyl)amino)quinoxaline derivatives as fgfr inhibitors for treating cancer
MX2021009426A (es) *	2019-02-11	2021-09-10	Merck Patent Gmbh	Derivados de indazolil-isoxazol para el tratamiento de enfermedades tales como cancer.
WO2020168197A1 (en)	2019-02-15	2020-08-20	Incyte Corporation	Pyrrolo[2,3-d]pyrimidinone compounds as cdk2 inhibitors
WO2020180959A1 (en)	2019-03-05	2020-09-10	Incyte Corporation	Pyrazolyl pyrimidinylamine compounds as cdk2 inhibitors
US11919904B2 (en)	2019-03-29	2024-03-05	Incyte Corporation	Sulfonylamide compounds as CDK2 inhibitors
WO2020210366A1 (en)	2019-04-09	2020-10-15	Plexxikon Inc.	Condensed azines for ep300 or cbp modulation and indications therefor
US11447494B2 (en)	2019-05-01	2022-09-20	Incyte Corporation	Tricyclic amine compounds as CDK2 inhibitors
WO2020223469A1 (en)	2019-05-01	2020-11-05	Incyte Corporation	N-(1-(methylsulfonyl)piperidin-4-yl)-4,5-di hydro-1h-imidazo[4,5-h]quinazolin-8-amine derivatives and related compounds as cyclin-dependent kinase 2 (cdk2) inhibitors for treating cancer
WO2020243519A1 (en) *	2019-05-29	2020-12-03	Ifm Due, Inc.	Compounds and compositions for treating conditions associated with sting activity
WO2020239124A1 (en) *	2019-05-31	2020-12-03	Fochon Pharmaceuticals, Ltd.	SUBSTITUTED PYRROLO [2, 3-b] PYRIDINE AND PYRAZOLO [3, 4-b] PYRIDINE DERIVATIVES AS PROTEIN KINASE INHIBITORS
KR20220046584A (ko)	2019-07-29	2022-04-14	헤파레게닉스 게엠베하	간 재생 촉진 또는 간세포 사멸 감소 또는 예방을 위한 헤테로아릴-치환된 피라졸로-피리딘 단백질 키나제 억제제
CN116348458A (zh)	2019-08-14	2023-06-27	因赛特公司	作为cdk2抑制剂的咪唑基嘧啶基胺化合物
WO2021067749A2 (en) *	2019-10-02	2021-04-08	The Board Of Trustees Of The Leland Stanford Junior University	Methods and compositions for the treatment of osteoarthritis
US11851426B2 (en)	2019-10-11	2023-12-26	Incyte Corporation	Bicyclic amines as CDK2 inhibitors
CN111004210A (zh) *	2019-10-23	2020-04-14	中山大学	化合物单晶及其制备方法
TW202136240A (zh)	2019-12-19	2021-10-01	美商亞文納營運公司	用於靶向降解雄激素受體之化合物及方法
WO2021134004A1 (en)	2019-12-27	2021-07-01	Schrodinger, Inc.	Cyclic compounds and methods of using same
US20230090552A1 (en)	2020-01-08	2023-03-23	Synthis Therapeutics, Inc.	Alk5 inhibitor conjugates and uses thereof
CA3164361A1 (en)	2020-01-15	2021-07-22	Heparegenix Gmbh	3-benzoyl-1h-pyrrolo[2,3-b]pyridine derivatives as mkk4 inhibitors for treating liver diseases
WO2021152005A1 (en)	2020-01-28	2021-08-05	Universite De Strasbourg	Antisense oligonucleotide targeting linc00518 for treating melanoma
MX2022012437A (es) *	2020-04-15	2022-10-27	Pyramid Biosciences Inc	Metodos para preparar inhibidores del receptor de la tirosina quinasa.
CN116323588A (zh)	2020-04-23	2023-06-23	奥普纳生物有限公司	用于cd73调节的化合物和方法及其适应症
US11833155B2 (en)	2020-06-03	2023-12-05	Incyte Corporation	Combination therapy for treatment of myeloproliferative neoplasms
US11529335B2 (en)	2020-07-31	2022-12-20	University Of Iowa Research Foundation	Compositions and methods for treating cancer
EP4199926A1 (en)	2020-08-21	2023-06-28	Plexxikon Inc.	Combinational drug anticancer therapies
WO2022055963A1 (en)	2020-09-10	2022-03-17	Schrödinger, Inc.	Heterocyclic pericondensed cdc7 kinase inhibitors for the treatment of cancer
WO2022063101A1 (zh) *	2020-09-23	2022-03-31	劲方医药科技(上海)有限公司	芳甲酰取代的三环化合物及其制法和用途
CN114478528A (zh) *	2020-10-28	2022-05-13	劲方医药科技(上海)有限公司	芳甲酰取代的三环化合物及其制法和用途
AU2021383227A1 (en) *	2020-11-17	2023-06-22	Fochon Biosciences, Ltd.	SUBSTITUTED PYRROLO [2, 3-b] PYRIDINE AND PYRAZOLO [3, 4-b] PYRIDINE DERIVATIVES AS PROTEIN KINASE INHIBITORS
WO2022125524A1 (en) *	2020-12-07	2022-06-16	Lieber Institute, Inc.	Compounds for inhibiting inositol hexakisphosphate kinase (ip6k) and methods of use thereof
CN116490504A (zh) *	2020-12-07	2023-07-25	浙江龙传生物医药科技有限公司	吡咯并吡啶类化合物及其应用
EP4267573A1 (en)	2020-12-23	2023-11-01	Genzyme Corporation	Deuterated colony stimulating factor-1 receptor (csf-1r) inhibitors
WO2022164789A1 (en)	2021-01-26	2022-08-04	Schrödinger, Inc.	Tricyclic compounds useful in the treatment of cancer, autoimmune and inflammatory disoders
CN112574200B (zh) *	2021-02-26	2021-06-11	安润医药科技（苏州）有限公司	Btk和/或btk的突变体c481s的小分子抑制剂
CN115073469B (zh) *	2021-03-15	2023-12-22	药雅科技(上海)有限公司	吡咯并嘧啶类化合物作为激酶抑制剂的制备及其应用
CN117321418A (zh)	2021-03-18	2023-12-29	诺华股份有限公司	癌症生物标志物及其使用方法
TW202300150A (zh)	2021-03-18	2023-01-01	美商薛定諤公司	環狀化合物及其使用方法
TW202304890A (zh) *	2021-04-14	2023-02-01	美商百歐克斯製藥公司	Klk5雙環雜芳香族抑制劑
WO2023059786A1 (en) *	2021-10-06	2023-04-13	H. Lee Moffitt Cancer Center And Research Institute, Inc.	Inhibitors of ulk1 and methods of use
WO2023174300A1 (zh) *	2022-03-15	2023-09-21	劲方医药科技(上海)有限公司	Btk抑制剂的晶型及其酸式盐和其酸式盐的晶型
WO2023178240A2 (en) *	2022-03-16	2023-09-21	The Children's Medical Center Corporation	Pyk2 inhibition modulates immune cell function
WO2024003350A1 (en)	2022-06-30	2024-01-04	Universite De Strasbourg	Combination therapy for melanoma
CN115141197B (zh) *	2022-07-27	2024-03-26	安徽医科大学	一种3-芳杂环取代苯基衍生物及其制备方法与用途
WO2024033381A1 (en)	2022-08-10	2024-02-15	Vib Vzw	Inhibition of tcf4/itf2 in the treatment of cancer
WO2024054591A1 (en)	2022-09-07	2024-03-14	Arvinas Operations, Inc.	Rapidly accelerated fibrosarcoma (raf) degrading compounds and associated methods of use

Family Cites Families (166)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3124610A (en) *		1964-03-10		Preparation of intermediates
US2234705A (en) *	1940-04-12	1941-03-11	Eastman Kodak Co	Cellulose organic derivative composition containing esters of monoalkoxy benzoic acids
US2413258A (en) *	1942-07-07	1946-12-24	United Gas Improvement Co	Polystyrene-type resins plasticized with high boiling fatty acid alkyl esters
US3067237A (en) *	1959-04-14	1962-12-04	Sterling Drug Inc	Lower-alkyl mono-or bis-(alkanesulfonamido) benzoate esters
GB1141949A (en)	1966-02-23	1969-02-05	Sterling Drug Inc	7-azaindole derivatives
BR6794063D0 (pt) *	1966-10-21	1973-09-18	Minnesota Mining & Mfg	Processo para preparar perfluoral-quilsulfonamidas n-substituidas e composicoes herbicidas e fitoreguladoras nelas baseadas
DE2413258A1 (de) *	1974-03-20	1975-10-02	Bayer Ag	Alkoxycarbonylphenylharnstoffe, verfahren zu ihrer herstellung und ihre verwendung als herbizide
AU7915675A (en) *	1974-03-20	1976-09-23	Bayer Ag	Alkoxycarbonylphenylureas
GB1573212A (en)	1976-04-15	1980-08-20	Technicon Instr	Immunoassay for gentamicin
US4301159A (en) *	1980-06-20	1981-11-17	Shionogi & Co., Ltd.	N-(Diethylaminoethyl)-2-alkoxy-benzamide derivatives
AU547405B2 (en) *	1981-07-08	1985-10-17	Sanofi	Amidobenzamides
US4664504A (en) *	1983-01-20	1987-05-12	Tokyo Shibaura Denki Kabushiki Kaisha	Image forming apparatus
US4568649A (en) *	1983-02-22	1986-02-04	Immunex Corporation	Immediate ligand detection assay
US4626513A (en) *	1983-11-10	1986-12-02	Massachusetts General Hospital	Method and apparatus for ligand detection
DE19775042I2 (de) *	1983-11-14	2001-05-03	Dowelanco	1, 2, 4-Triazolo 1, 4-a pyrimidin-2-Sulfonamide und zubereitungen und Methode zur Bekaempfung unerwuenschter Pflanzen und die Nitrierung von Ammonium-Stickstoff im Boden
AU567140B2 (en) *	1984-01-06	1987-11-12	Shionogi & Co., Ltd.	Sulphonamido-benzamide derivatives
EP0154734B1 (en)	1984-03-15	1990-08-29	Immunex Corporation	Immediate ligand detection assay, a test kit and its formation
IT1196133B (it) *	1984-06-06	1988-11-10	Ausonia Farma Srl	Derivati furanici con attivita' antiulcera
US4714693A (en)	1986-04-03	1987-12-22	Uop Inc.	Method of making a catalyst composition comprising uniform size metal components on carrier
US5688655A (en) *	1988-02-10	1997-11-18	Ict Pharmaceuticals, Inc.	Method of screening for protein inhibitors and activators
US6054270A (en) *	1988-05-03	2000-04-25	Oxford Gene Technology Limited	Analying polynucleotide sequences
US5700637A (en) *	1988-05-03	1997-12-23	Isis Innovation Limited	Apparatus and method for analyzing polynucleotide sequences and method of generating oligonucleotide arrays
US5658775A (en) *	1988-05-17	1997-08-19	Sloan-Kettering Institute For Cancer Research	Double copy retroviral vector
EP0432216A1 (en) *	1988-09-01	1991-06-19	Whitehead Institute For Biomedical Research	Recombinant retroviruses with amphotropic and ecotropic host ranges
US5703055A (en) *	1989-03-21	1997-12-30	Wisconsin Alumni Research Foundation	Generation of antibodies through lipid mediated DNA delivery
US5143854A (en) *	1989-06-07	1992-09-01	Affymax Technologies N.V.	Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof
US5527681A (en) *	1989-06-07	1996-06-18	Affymax Technologies N.V.	Immobilized molecular synthesis of systematically substituted compounds
US5800992A (en) *	1989-06-07	1998-09-01	Fodor; Stephen P.A.	Method of detecting nucleic acids
US5744101A (en) *	1989-06-07	1998-04-28	Affymax Technologies N.V.	Photolabile nucleoside protecting groups
US5360822A (en) *	1990-02-07	1994-11-01	Nippon Shinyaku Co. Ltd.	Sulfonanilide derivatives and medicine
WO1991018088A1 (en) *	1990-05-23	1991-11-28	The United States Of America, Represented By The Secretary, United States Department Of Commerce	Adeno-associated virus (aav)-based eucaryotic vectors
DE4022414A1 (de) *	1990-07-13	1992-01-16	Bayer Ag	Substituierte pyrrolo-pyridine
US5124335A (en)	1991-01-30	1992-06-23	Merck & Co., Inc.	Substituted pyrollo-fused 6 membered heterocycles as angiotensin ii antagonists
WO1993002556A1 (en) *	1991-07-26	1993-02-18	University Of Rochester	Cancer therapy utilizing malignant cells
US5632957A (en) *	1993-11-01	1997-05-27	Nanogen	Molecular biological diagnostic systems including electrodes
FR2687402B1 (fr) *	1992-02-14	1995-06-30	Lipha	Nouveaux azaindoles, procedes de preparation et medicaments les contenant.
JPH05236997A (ja) *	1992-02-28	1993-09-17	Hitachi Ltd	ポリヌクレオチド捕捉用チップ
US5576319A (en) *	1993-03-01	1996-11-19	Merck, Sharp & Dohme Ltd.	Pyrrolo-pyridine derivatives
HUT71799A (en) *	1993-03-01	1996-02-28	Merck Sharp & Dohme	Pyrrolo-pyridine derivatives, pharmaceutical compositions containing the same, process for producing them
DE69420394T2 (de) *	1993-03-01	2000-04-13	Merck Sharp & Dohme	Pyrrolopyridinderivate als dopaminrezeptor liganden
US5549614A (en) *	1993-03-18	1996-08-27	Tunis; Scott W.	Apparatus for folding flexible intraocular lenses
NZ267843A (en) *	1993-05-27	1997-10-24	Selectide Corp	Libraries of synthetic test compound attached to separate phase synthesis supports
US5840485A (en) *	1993-05-27	1998-11-24	Selectide Corporation	Topologically segregated, encoded solid phase libraries
US5631236A (en) *	1993-08-26	1997-05-20	Baylor College Of Medicine	Gene therapy for solid tumors, using a DNA sequence encoding HSV-Tk or VZV-Tk
US5426039A (en) *	1993-09-08	1995-06-20	Bio-Rad Laboratories, Inc.	Direct molecular cloning of primer extended DNA containing an alkane diol
JP3545461B2 (ja)	1993-09-10	2004-07-21	エーザイ株式会社	二環式ヘテロ環含有スルホンアミド誘導体
US6045996A (en) *	1993-10-26	2000-04-04	Affymetrix, Inc.	Hybridization assays on oligonucleotide arrays
US6468742B2 (en) *	1993-11-01	2002-10-22	Nanogen, Inc.	Methods for determination of single nucleic acid polymorphisms using bioelectronic microchip
US5965452A (en) *	1996-07-09	1999-10-12	Nanogen, Inc.	Multiplexed active biologic array
US5486525A (en) *	1993-12-16	1996-01-23	Abbott Laboratories	Platelet activating factor antagonists: imidazopyridine indoles
US5807522A (en) *	1994-06-17	1998-09-15	The Board Of Trustees Of The Leland Stanford Junior University	Methods for fabricating microarrays of biological samples
US5763198A (en) *	1994-07-22	1998-06-09	Sugen, Inc.	Screening assays for compounds
GB9416189D0 (en)	1994-08-10	1994-09-28	Merck Sharp & Dohme	Therapeutic agents
GB9416162D0 (en)	1994-08-10	1994-09-28	Merck Sharp & Dohme	Therapeutic agents
DE4430212A1 (de) *	1994-08-28	1996-02-29	Merck Patent Gmbh	Ortho-substituierte Benzoesäure-Derivate
US5556752A (en) *	1994-10-24	1996-09-17	Affymetrix, Inc.	Surface-bound, unimolecular, double-stranded DNA
US5830645A (en) *	1994-12-09	1998-11-03	The Regents Of The University Of California	Comparative fluorescence hybridization to nucleic acid arrays
GB9503400D0 (en)	1995-02-21	1995-04-12	Merck Sharp & Dohme	Therpeutic agents
GB2298199A (en) *	1995-02-21	1996-08-28	Merck Sharp & Dohme	Synthesis of azaindoles
US5959098A (en) *	1996-04-17	1999-09-28	Affymetrix, Inc.	Substrate preparation process
US6117681A (en) *	1995-03-29	2000-09-12	Bavarian Nordic Research Inst. A/S	Pseudotyped retroviral particles
GB9507291D0 (en) *	1995-04-07	1995-05-31	Merck Sharp & Dohme	Therapeutic agents
GB2299581A (en)	1995-04-07	1996-10-09	Merck Sharp & Dohme	3-(Tetrahydropyridin-1-yl-methyl)pyrrolo[2,3-b]pyridine derivatives as ligands for dopamine receptor subtypes
US6110456A (en) *	1995-06-07	2000-08-29	Yale University	Oral delivery or adeno-associated viral vectors
US5856174A (en) *	1995-06-29	1999-01-05	Affymetrix, Inc.	Integrated nucleic acid diagnostic device
US5866411A (en) *	1995-09-08	1999-02-02	Pedersen; Finn Skou	Retroviral vector, a replication system for said vector and avian or mammalian cells transfected with said vector
US5747276A (en) *	1995-09-15	1998-05-05	The Scripps Research Institute	Screening methods for the identification of novel antibiotics
WO1997016533A1 (en) *	1995-10-31	1997-05-09	The Regents Of The University Of California	Mammalian artificial chromosomes and methods of using same
US6022963A (en) *	1995-12-15	2000-02-08	Affymetrix, Inc.	Synthesis of oligonucleotide arrays using photocleavable protecting groups
US6013440A (en) *	1996-03-11	2000-01-11	Affymetrix, Inc.	Nucleic acid affinity columns
US6025155A (en) *	1996-04-10	2000-02-15	Chromos Molecular Systems, Inc.	Artificial chromosomes, uses thereof and methods for preparing artificial chromosomes
US5804585A (en) *	1996-04-15	1998-09-08	Texas Biotechnology Corporation	Thieno-pyridine sulfonamides derivatives thereof and related compounds that modulate the activity of endothelin
DE69728688T2 (de) *	1996-11-19	2004-08-19	Amgen Inc., Thousand Oaks	Aryl und heteroaryl substituierte kondensierte pyrrole als entzündunghemmende mittel
US6294330B1 (en) *	1997-01-31	2001-09-25	Odyssey Pharmaceuticals Inc.	Protein fragment complementation assays for the detection of biological or drug interactions
EP0972071A4 (en) *	1997-03-07	2004-04-21	Tropix Inc	TEST ARRANGEMENT FOR PROTEAS INHIBITORS
US5977131A (en)	1997-04-09	1999-11-02	Pfizer Inc.	Azaindole-ethylamine derivatives as nicotinic acetylcholine receptor binding agents
US6096718A (en) *	1997-06-05	2000-08-01	Gene Targeting Corp.	Tissue specific adenovirus vectors for breast cancer treatment
CN1268942A (zh)	1997-06-27	2000-10-04	藤泽药品工业株式会社	磺酰胺化合物及其药物用途
US6235769B1 (en) *	1997-07-03	2001-05-22	Sugen, Inc.	Methods of preventing and treating neurological disorders with compounds that modulate the function of the C-RET receptor protein tyrosine kinase
US6826296B2 (en) *	1997-07-25	2004-11-30	Affymetrix, Inc.	Method and system for providing a probe array chip design database
US6161776A (en) *	1997-08-12	2000-12-19	Nibco Inc.	Multi-layered, porous mat turf irrigation apparatus and method
ES2190591T3 (es) *	1997-09-11	2003-08-01	Bioventures Inc	Metodo de producir disposiciones ordenadas de alta densidad.
US6178384B1 (en) *	1997-09-29	2001-01-23	The Trustees Of Columbia University In The City Of New York	Method and apparatus for selecting a molecule based on conformational free energy
US6465178B2 (en) *	1997-09-30	2002-10-15	Surmodics, Inc.	Target molecule attachment to surfaces
US6048695A (en) *	1998-05-04	2000-04-11	Baylor College Of Medicine	Chemically modified nucleic acids and methods for coupling nucleic acids to solid support
CA2319495A1 (en) *	1998-06-08	1999-12-16	Advanced Medicine, Inc.	Multibinding inhibitors of microsomal triglyceride transferase protein
US6113913A (en) *	1998-06-26	2000-09-05	Genvec, Inc.	Recombinant adenovirus
US6184226B1 (en)	1998-08-28	2001-02-06	Scios Inc.	Quinazoline derivatives as inhibitors of P-38 α
CN1261098C (zh)	1998-08-28	2006-06-28	西奥斯股份有限公司	p38－α激酶的抑制剂
US6350786B1 (en) *	1998-09-22	2002-02-26	Hoffmann-La Roche Inc.	Stable complexes of poorly soluble compounds in ionic polymers
US6277628B1 (en) *	1998-10-02	2001-08-21	Incyte Genomics, Inc.	Linear microarrays
US6277489B1 (en) *	1998-12-04	2001-08-21	The Regents Of The University Of California	Support for high performance affinity chromatography and other uses
US20010001449A1 (en)	1998-12-30	2001-05-24	Thomas R. Kiliany	Low-pressure hydrocracking process
EP1163237B1 (en) *	1999-03-17	2004-05-06	AstraZeneca AB	Amide derivatives
GB9906566D0 (en)	1999-03-23	1999-05-19	Zeneca Ltd	Chemical compounds
US6221653B1 (en) *	1999-04-27	2001-04-24	Agilent Technologies, Inc.	Method of performing array-based hybridization assays using thermal inkjet deposition of sample fluids
FR2793793B1 (fr) *	1999-05-19	2004-02-27	Adir	Nouveaux derives dimeriques substitues, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
TWI234557B (en) *	1999-05-26	2005-06-21	Telik Inc	Novel naphthalene ureas as glucose uptake enhancers
US6653151B2 (en) *	1999-07-30	2003-11-25	Large Scale Proteomics Corporation	Dry deposition of materials for microarrays using matrix displacement
US20010008765A1 (en) *	1999-12-06	2001-07-19	Fuji Photo Film Co., Ltd.	DNA chip and reactive solid carrier
CA2395461C (en) *	1999-12-22	2010-05-25	Sugen, Inc.	Methods of modulating c-kit tyrosine kinase function with indolinone compounds
AU776933B2 (en)	1999-12-28	2004-09-23	Eisai R&D Management Co., Ltd.	Heterocyclic compounds having sulfonamide groups
JP2001278886A (ja) *	2000-03-28	2001-10-10	Dai Ichi Seiyaku Co Ltd	ベンゾオキサジン誘導体及びこれを含有する医薬
GB0007934D0 (en) *	2000-03-31	2000-05-17	Darwin Discovery Ltd	Chemical compounds
CA2438427C (en)	2001-02-21	2011-04-12	Eisai Co., Ltd.	Method for testing effect of angiogenesis inhibitor via integrin expression inhibition
CN101310771B (zh)	2001-04-11	2012-08-08	千寿制药株式会社	视觉功能障碍改善剂
AU2002258971A1 (en)	2001-04-24	2002-11-05	Wyeth	Antidepressant azaheterocyclylmethyl derivatives of 2,3-dihydro-1,4-benzodioxan
GB0114417D0 (en) *	2001-06-13	2001-08-08	Boc Group Plc	Lubricating systems for regenerative vacuum pumps
WO2002102783A1 (en)	2001-06-19	2002-12-27	Merck & Co., Inc.	Tyrosine kinase inhibitors
US7291639B2 (en)	2001-06-20	2007-11-06	Wyeth	Aryloxy-acetic acid compounds useful as inhibitors of plasminogen activator inhibitor-1 (PAI-1)
GB0115109D0 (en) *	2001-06-21	2001-08-15	Aventis Pharma Ltd	Chemical compounds
UA75425C2 (en)	2001-07-09	2006-04-17		Piperazine oxime derivatives with antagonistic activity to nk-1 receptor, use thereof, a pharmaceutical composition based thereon, a method for producing and a method for producing intermediary compounds
GB0117583D0 (en)	2001-07-19	2001-09-12	Astrazeneca Ab	Novel compounds
US6858860B2 (en) *	2001-07-24	2005-02-22	Seiko Epson Corporation	Apparatus and method for measuring natural period of liquid
GB0118479D0 (en)	2001-07-28	2001-09-19	Astrazeneca Ab	Novel compounds
WO2003028724A1 (en)	2001-10-04	2003-04-10	Smithkline Beecham Corporation	Chk1 kinase inhibitors
WO2003037862A1 (fr)	2001-10-30	2003-05-08	Nippon Shinyaku Co., Ltd.	Derives amide, et medicaments correspondants
US20030236277A1 (en)	2002-02-14	2003-12-25	Kadow John F.	Indole, azaindole and related heterocyclic pyrrolidine derivatives
US6884889B2 (en)	2002-03-25	2005-04-26	Bristol-Myers Squibb Co.	Processes for the preparation of antiviral 7-azaindole derivatives
CN100338062C (zh)	2002-03-28	2007-09-19	卫材株式会社	作为c－Jun N－末端激酶抑制剂的氮杂吲哚类化合物
WO2003082868A1 (en)	2002-03-28	2003-10-09	Eisai Co., Ltd.	7-azaindoles as inhibitors of c-jun n-terminal kinases for the treatment of neurodegenerative disorders
GB0212785D0 (en) *	2002-05-31	2002-07-10	Glaxo Group Ltd	Compounds
UA78999C2 (en)	2002-06-04	2007-05-10	Wyeth Corp	1-(aminoalkyl)-3-sulfonylazaindoles as ligands of 5-hydroxytryptamine-6
TW200403243A (en)	2002-07-18	2004-03-01	Wyeth Corp	1-Heterocyclylalkyl-3-sulfonylazaindole or-azaindazole derivatives as 5-hydroxytryptamine-6 ligands
TWI329112B (en)	2002-07-19	2010-08-21	Bristol Myers Squibb Co	Novel inhibitors of kinases
US6878887B2 (en) *	2002-08-07	2005-04-12	Matsushita Electric Industrial Co., Ltd.	Anti-malfunction mechanism for variable output device
SE0202463D0 (sv) *	2002-08-14	2002-08-14	Astrazeneca Ab	Novel compounds
KR20120104412A (ko)	2002-09-06	2012-09-20	인설트 테라페틱스, 인코퍼레이티드	공유결합된 치료제 전달을 위한 사이클로덱스트린-기초 중합체
US20040142864A1 (en)	2002-09-16	2004-07-22	Plexxikon, Inc.	Crystal structure of PIM-1 kinase
CA2509711A1 (en) *	2002-12-13	2004-07-01	Smithkline Beecham Corporation	Piperidine derivatives as ccr5 antagonists
AU2003297048A1 (en) *	2002-12-13	2004-07-09	Smithkline Beecham Corporation	Cyclohexyl compounds as ccr5 antagonists
US7696225B2 (en) *	2003-01-06	2010-04-13	Osi Pharmaceuticals, Inc.	(2-carboxamido)(3-Amino) thiophene compounds
SE0300120D0 (sv)	2003-01-17	2003-01-17	Astrazeneca Ab	Novel compounds
SE0300119D0 (sv)	2003-01-17	2003-01-17	Astrazeneca Ab	Novel compounds
US20050085463A1 (en) *	2003-01-23	2005-04-21	Weiner David M.	Use of N-desmethylclozapine to treat human neuropsychiatric disease
TW200418830A (en) *	2003-02-14	2004-10-01	Wyeth Corp	Heterocyclyl-3-sulfonylazaindole or-azaindazole derivatives as 5-hydroxytryptamine-6 ligands
US20050170431A1 (en) *	2003-02-28	2005-08-04	Plexxikon, Inc.	PYK2 crystal structure and uses
WO2005028624A2 (en)	2003-09-15	2005-03-31	Plexxikon, Inc.	Molecular scaffolds for kinase ligand development
DE10357510A1 (de)	2003-12-09	2005-07-07	Bayer Healthcare Ag	Heteroarylsubstituierte Benzole
EP1696920B8 (en)	2003-12-19	2015-05-06	Plexxikon Inc.	Compounds and methods for development of ret modulators
BRPI0417533B1 (pt)	2003-12-24	2016-03-01	Danisco	enzima variante glicolipídio aciltransferase, uso e método para sua produção, método para o preparo de um produto alimentício e produto assado de farinha, processo de refinamento enzimático
GB0330042D0 (en)	2003-12-24	2004-01-28	Pharmacia Italia Spa	Pyrrolo [2,3-b] pyridine derivatives active as kinase inhibitors process for their preparation and pharmaceutical compositions them
GB0330043D0 (en)	2003-12-24	2004-01-28	Pharmacia Italia Spa	Pyrrolo [2,3-b] pyridine derivatives active as kinase inhibitors process for their preparation and pharmaceutical compositions comprising them
GB0403635D0 (en)	2004-02-18	2004-03-24	Devgen Nv	Pyridinocarboxamides with improved activity as kinase inhibitors
GB0405055D0 (en)	2004-03-05	2004-04-07	Eisai London Res Lab Ltd	JNK inhibitors
PL2332940T3 (pl)	2004-03-30	2013-03-29	Vertex Pharma	Azaindole użyteczne jako inhibitory JAK i innych kinaz białkowych
US20060058339A1 (en) *	2004-06-17	2006-03-16	Ibrahim Prabha N	Compounds modulating c-kit activity and uses therefor
US7498342B2 (en) *	2004-06-17	2009-03-03	Plexxikon, Inc.	Compounds modulating c-kit activity
EP1765819B1 (en)	2004-06-30	2014-03-12	Vertex Pharmaceuticals Inc.	Azaindoles useful as inhibitors of protein kinases
US7709645B2 (en) *	2004-07-27	2010-05-04	Sgx Pharmaceuticals, Inc.	Pyrrolo-pyridine kinase modulators
JP2008508303A (ja) *	2004-07-27	2008-03-21	エスジーエックスファーマシューティカルズ、インコーポレイテッド	ピロロ−ピリジンキナーゼモジュレーター
US7361764B2 (en) *	2004-07-27	2008-04-22	Sgx Pharmaceuticals, Inc.	Pyrrolo-pyridine kinase modulators
CA2573573A1 (en) *	2004-07-27	2006-02-09	Sgx Pharmaceuticals, Inc.	Fused ring heterocycle kinase modulators
US7626021B2 (en) *	2004-07-27	2009-12-01	Sgx Pharmaceuticals, Inc.	Fused ring heterocycle kinase modulators
GB0419192D0 (en) *	2004-08-27	2004-09-29	Merck Sharp & Dohme	Therapeutic agents
ATE524467T1 (de)	2005-04-25	2011-09-15	Merck Patent Gmbh	Neuartige aza-heterozyklen als kinase-inhibitoren
KR20080027775A (ko) *	2005-05-17	2008-03-28	플렉시콘, 인코퍼레이티드	피롤(２,３-ｂ)피리딘 유도체 단백질 키나제 억제제
MX2007014619A (es)	2005-05-20	2009-02-13	Vertex Pharma	Pirrolopiridinas de utilidad como inhibidores de proteina quinasa.
CN102603581B (zh) *	2005-06-22	2015-06-24	普莱希科公司	作为蛋白质激酶抑制剂的吡咯并[2,3-b]吡啶衍生物
GB0516156D0 (en)	2005-08-05	2005-09-14	Eisai London Res Lab Ltd	JNK inhibitors
TW200812611A (en) *	2006-03-20	2008-03-16	Vertex Pharma	Pharmaceutical compositions
WO2008063888A2 (en) *	2006-11-22	2008-05-29	Plexxikon, Inc.	Compounds modulating c-fms and/or c-kit activity and uses therefor
WO2008079909A1 (en) *	2006-12-21	2008-07-03	Plexxikon, Inc.	Pyrrolo [2,3-b] pyridines as kinase modulators
PE20081581A1 (es)	2006-12-21	2008-11-12	Plexxikon Inc	COMPUESTOS PIRROLO[2,3-b]PIRIDINAS COMO MODULADORES DE QUINASA
CL2008001540A1 (es) *	2007-05-29	2009-05-22	Sgx Pharmaceuticals Inc	Compuestos derivados de pirrolopiridinas y pirazolopiridinas; composicion farmaceutica; y uso en el tratamiento del cancer.
TW201041888A (en) *	2009-05-06	2010-12-01	Plexxikon Inc	Compounds and methods for kinase modulation, and indications therefor

2006
- 2006-06-21 CN CN201210012143.5A patent/CN102603581B/zh active Active
- 2006-06-21 NZ NZ565255A patent/NZ565255A/en unknown
- 2006-06-21 EP EP16151919.4A patent/EP3088400A1/en not_active Withdrawn
- 2006-06-21 TW TW103130685A patent/TWI522337B/zh active
- 2006-06-21 UA UAA200800780A patent/UA95244C2/ru unknown
- 2006-06-21 JP JP2008518402A patent/JP5007304B2/ja active Active
- 2006-06-21 MX MX2007016463A patent/MX2007016463A/es active IP Right Grant
- 2006-06-21 PL PL06773861T patent/PL1893612T3/pl unknown
- 2006-06-21 ES ES11173701.1T patent/ES2565992T3/es active Active
- 2006-06-21 PT PT06773861T patent/PT1893612E/pt unknown
- 2006-06-21 WO PCT/US2006/024524 patent/WO2007002433A1/en active Application Filing
- 2006-06-21 KR KR1020087001659A patent/KR101125919B1/ko active Protection Beyond IP Right Term
- 2006-06-21 EP EP06773861A patent/EP1893612B1/en active Active
- 2006-06-21 CN CN2006800303262A patent/CN101243084B/zh active Active
- 2006-06-21 TW TW095122373A patent/TWI432193B/zh active
- 2006-06-21 PE PE2006000690A patent/PE20070100A1/es active IP Right Grant
- 2006-06-21 US US11/473,347 patent/US7863288B2/en active Active
- 2006-06-21 RU RU2008100933/04A patent/RU2418800C2/ru active Protection Beyond IP Right Term
- 2006-06-21 EP EP11173701.1A patent/EP2395004B1/en active Active
- 2006-06-21 SI SI200631158T patent/SI1893612T1/sl unknown
- 2006-06-21 AT AT06773861T patent/ATE518860T1/de active
- 2006-06-21 PL PL11173701T patent/PL2395004T3/pl unknown
- 2006-06-21 SI SI200632039A patent/SI2395004T1/sl unknown
- 2006-06-21 CA CA2613015A patent/CA2613015C/en active Active
- 2006-06-21 AU AU2006261993A patent/AU2006261993B2/en active Active
- 2006-06-21 DK DK11173701.1T patent/DK2395004T3/en active
- 2006-06-21 RU RU2011101140/04A patent/RU2565071C2/ru active
- 2006-06-21 ES ES06773861T patent/ES2371397T3/es active Active
- 2006-06-21 HU HUE11173701A patent/HUE027370T2/en unknown
- 2006-06-21 CN CN201110084299.XA patent/CN102206216B/zh active Active
- 2006-06-21 DK DK06773861.7T patent/DK1893612T3/da active
- 2006-06-21 WO PCT/US2006/024361 patent/WO2007002325A1/en active Application Filing
- 2006-06-21 RS RS20110485A patent/RS52010B/en unknown
- 2006-06-21 TW TW102123382A patent/TWI473808B/zh active
- 2006-06-21 BR BRPI0611863-1A patent/BRPI0611863B1/pt active IP Right Grant
- 2006-06-21 MY MYPI2011004969A patent/MY153898A/en unknown
- 2006-06-21 MY MYPI20062939A patent/MY147410A/en unknown
- 2006-06-22 AR ARP060102668A patent/AR054624A1/es active IP Right Grant
2007
- 2007-12-19 IL IL188248A patent/IL188248A/en active IP Right Grant
- 2007-12-20 ZA ZA2007/11152A patent/ZA200711152B/en unknown
- 2007-12-28 NO NO20076659A patent/NO333913B1/no active Protection Beyond IP Right Term
2008
- 2008-01-07 MA MA30548A patent/MA29612B1/fr unknown
- 2008-01-18 EC EC2008008121A patent/ECSP088121A/es unknown
- 2008-01-22 CR CR9677A patent/CR9677A/es unknown
- 2008-09-05 HK HK08109870.8A patent/HK1114610A1/xx unknown
2009
- 2009-11-10 US US12/616,079 patent/US8415469B2/en active Active
2010
- 2010-10-04 AR ARP100103601A patent/AR078519A2/es active IP Right Grant
- 2010-10-18 US US12/906,980 patent/US8470818B2/en active Active
2011
- 2011-08-23 US US13/216,200 patent/US8143271B2/en active Active - Reinstated
- 2011-09-23 US US13/243,748 patent/US20120053177A1/en not_active Abandoned
- 2011-11-03 CY CY20111101061T patent/CY1111996T1/el unknown
2012
- 2012-03-19 ZA ZA2012/02025A patent/ZA201202025B/en unknown
- 2012-03-19 ZA ZA2012/02026A patent/ZA201202026B/en unknown
- 2012-03-19 ZA ZA2012/02024A patent/ZA201202024B/en unknown
- 2012-06-07 HK HK12105582.9A patent/HK1164866A1/zh unknown
- 2012-06-26 HU HUS1200009C patent/HUS1200009I1/hu unknown
- 2012-06-26 DE DE201212000043 patent/DE122012000043I1/de active Pending
- 2012-06-28 LU LU92035C patent/LU92035I2/fr unknown
- 2012-07-31 CY CY2012021C patent/CY2012021I1/el unknown
- 2012-11-28 RU RU2012150759A patent/RU2629999C2/ru active
2013
- 2013-03-05 US US13/786,219 patent/US20130303534A1/en not_active Abandoned
- 2013-04-19 US US13/866,469 patent/US20130261117A1/en not_active Abandoned
- 2013-05-10 CR CR20130216A patent/CR20130216A/es unknown
2014
- 2014-03-20 NO NO2014006C patent/NO2014006I1/no not_active IP Right Cessation
2015
- 2015-01-21 US US14/602,119 patent/US20150290205A1/en not_active Abandoned
- 2015-07-13 US US14/798,167 patent/US20160176865A1/en not_active Abandoned
2017
- 2017-05-25 US US15/605,856 patent/US20180111929A1/en not_active Abandoned

Also Published As

Publication number	Publication date
ZA201202024B (en)	2016-02-24
US20160176865A1 (en)	2016-06-23
CN101243084A (zh)	2008-08-13
US20110059963A1 (en)	2011-03-10
PT1893612E (pt)	2011-11-21
PL1893612T3 (pl)	2012-01-31
HK1114610A1 (en)	2008-11-07
CR20130216A (es)	2013-07-02
NO20076659L (no)	2008-03-18
CN102206216B (zh)	2014-11-12
HUS1200009I1 (hu)	2018-09-28
CY2012021I2 (el)	2015-08-05
US20120053177A1 (en)	2012-03-01
WO2007002433A1 (en)	2007-01-04
MX2007016463A (es)	2008-03-04
SI2395004T1 (sl)	2016-05-31
PL2395004T3 (pl)	2016-08-31
US20100256365A1 (en)	2010-10-07
CR9677A (es)	2008-03-26
EP3088400A1 (en)	2016-11-02
IL188248A (en)	2012-04-30
JP5007304B2 (ja)	2012-08-22
ES2565992T3 (es)	2016-04-08
ZA201202026B (en)	2012-11-28
MY153898A (en)	2015-04-15
DE122012000043I1 (de)	2012-09-13
RU2012150759A (ru)	2014-06-10
US20130261117A1 (en)	2013-10-03
AU2006261993A1 (en)	2007-01-04
ZA201202025B (en)	2022-03-30
HK1164866A1 (zh)	2012-09-28
CY2012021I1 (el)	2015-08-05
DK2395004T3 (en)	2016-03-21
TWI473808B (zh)	2015-02-21
NZ565255A (en)	2010-04-30
RU2008100933A (ru)	2009-07-27
TWI432193B (zh)	2014-04-01
PE20070100A1 (es)	2007-03-10
NO2014006I2 (no)	2014-03-20
EP2395004A3 (en)	2012-04-04
RU2011101140A (ru)	2012-07-20
TWI522337B (zh)	2016-02-21
CN102603581A (zh)	2012-07-25
KR101125919B1 (ko)	2012-06-12
AR054624A1 (es)	2007-07-04
US20150290205A1 (en)	2015-10-15
TW200804370A (en)	2008-01-16
NO2014006I1 (no)	2014-06-02
LU92035I9 (ru)	2019-01-04
ATE518860T1 (de)	2011-08-15
US8415469B2 (en)	2013-04-09
ZA200711152B (en)	2012-06-27
EP1893612B1 (en)	2011-08-03
IL188248A0 (en)	2008-04-13
NO333913B1 (no)	2013-10-21
MA29612B1 (fr)	2008-07-01
ES2371397T3 (es)	2011-12-30
DK1893612T3 (da)	2011-11-21
US8470818B2 (en)	2013-06-25
US20100249118A1 (en)	2010-09-30
MY147410A (en)	2012-11-30
CN102603581B (zh)	2015-06-24
WO2007002325A1 (en)	2007-01-04
JP2008546797A (ja)	2008-12-25
TW201514140A (zh)	2015-04-16
SI1893612T1 (sl)	2012-03-30
TW201345906A (zh)	2013-11-16
CN102206216A (zh)	2011-10-05
US20130303534A1 (en)	2013-11-14
CN101243084B (zh)	2012-03-07
ECSP088121A (es)	2008-02-20
EP2395004A2 (en)	2011-12-14
RU2418800C2 (ru)	2011-05-20
RU2629999C2 (ru)	2017-09-05
KR20080030619A (ko)	2008-04-04
US20120022098A1 (en)	2012-01-26
CY1111996T1 (el)	2015-08-05
LU92035I2 (fr)	2012-08-28
US8143271B2 (en)	2012-03-27
US20180111929A1 (en)	2018-04-26
AR078519A2 (es)	2011-11-16
RU2565071C2 (ru)	2015-10-20
HUE027370T2 (en)	2016-10-28
CA2613015A1 (en)	2007-01-04
EP2395004B1 (en)	2016-01-20
RS52010B (en)	2012-04-30
BRPI0611863A2 (pt)	2008-12-02
BRPI0611863B1 (pt)	2021-11-23
US7863288B2 (en)	2011-01-04
CA2613015C (en)	2012-04-03
AU2006261993B2 (en)	2011-11-17
EP1893612A1 (en)	2008-03-05

Publication	Publication Date	Title
UA95244C2 (ru)	2011-07-25	Соединения и способ модулирования активности киназ, и показания для их применения
MY148468A (en)	2013-04-30	Compounds and methods for kinase modulation, and indications therefor
MX2009006688A (es)	2009-06-30	Compuestos y metodos para modulacion de cinasas, e indicaciones para ello.
EA200970402A1 (ru)	2009-10-30	Триазолопиридазиновые модуляторы протеинкиназ
EA200870048A1 (ru)	2009-02-27	ГЕТЕРОАРИЛ-ЗЕМЕЩЕННЫЕ ПИРРОЛО[2,3-b]ПИРИДИНЫ И ПИРРОЛО[2,3-b]ПИРИМИДИНЫ В КАЧЕСТВЕ ИНГИБИТОРОВ ЯНУС-КИНАЗЫ
MX358128B (es)	2018-08-06	Compuestos y métodos para la modulación de quinasas e indicaciones para los mismos.
EA200801291A1 (ru)	2008-12-30	Карбониламинопирролопиразолы в качестве эффективных ингибиторов киназ
WO2009143024A3 (en)	2010-01-07	Compounds and methods for kinase modulation, and indications therefor
UA97816C2 (en)	2012-03-26	Compounds modulating c-kit and/or c-fms activity and use thereof
EA200970403A1 (ru)	2009-10-30	Бициклические триазолы в качестве модуляторов протеинкиназы
PH12015501370A1 (en)	2015-09-02	Compounds and methods for kinase modulation, and indications therefor
EA200971077A1 (ru)	2010-04-30	Гетероциклические модуляторы киназы
TW200801008A (en)	2008-01-01	Protein kinase inhibitors
MX2009011210A (es)	2009-10-30	Inhibidores de mcl1 de indol 7-no sustituido.
EA200970738A1 (ru)	2010-06-30	Ингибиторы активности akt
GEP20156251B (en)	2015-02-25	Compounds and methods for kinase modulation, and indications therefor
TW200614990A (en)	2006-05-16	Methods for preparing indazole compounds
EA201100580A1 (ru)	2011-10-31	Имидазопиридазинкарбонитрилы, используемые в качестве ингибиторов киназы
MX2009006170A (es)	2009-06-19	Compuestos y composiciones como inhibidores de cinasa.
TW200716132A (en)	2007-05-01	Novel chemical compounds
TW200716579A (en)	2007-05-01	Novel chemical compounds
MX2009012079A (es)	2009-11-19	Compuestos heterociclicos condensados como inhibidores de proteina cinasas.
UA92047C2 (ru)	2010-09-27	Карбониламинопирролпиразолы - мощные ингибиторы киназы
UA88794C2 (en)	2009-11-25	Pyrrolopyrazoles, potent kinase inhibitors
EA202091617A1 (ru)	2020-10-30	Гетероарил-замещенные пирроло[2,3-b]пиридины и пирроло[2,3-b]пиримидины в качестве ингибиторов янус-киназы